MODIGENE - 53 Mrd. $ Proteinmarkt - 500 Beiträge pro Seite

[BikiniAnalyst]

Hi Freunde!

Ich dachte es ist an der Zeit zu folgender Aktie aus dem Biotech-Bereich mal eine Diskussion zu eröffnen. Zuerst möchte ich hier einige Fakten einstellen:



Name: Modigene Inc.
Börsenkürzel Dtld: M3D
Kürzel USA: MODG
WKN: A0MSLD
ISIN: US6078261046
Anzahl der Aktien: 42,3 Mio.
Market Cap: 69,3 Mio. €

Kurs (19.06.2007): 1,64 € bzw. 2,20 US-$

Branche: Biotechnologie

Homepage: www.modigeneinc.com

-------------------------------------------------------

Dr. Philip Frost, der berühmte Biotechnologie-Magnat der im Jahr 2006 zu den 700 reichsten Menschen des Planeten gehörte und vor kurzem in Modigene investierte und diese mittels seiner Aufsichtsratposition auch berät, verkündete Mitte Mai
2007:
„Wir sind ganz aufgeregt über die Möglichkeiten durch Modigene und glauben an das Management-Team, den Produkten und der zugrunde liegenden Technologie. Wir freuen uns auf die Zusammenarbeit mit dem Management und dem Aufsichtsrat, um Modigene zu einem signifikanten Player im therapeutischen Proteinmarkt aufzubauen.“

------------------------

Modigene Inc. ist ein in der Stadt Vienna, Virginia (USA) beheimates Biotechnologie-Unternehmen (mit einer eigenen Forschungs-& Entwicklungs-Einrichtung namens ModigeneTech Ltd. im Weizmann Science Park in Nes Ziona, Israel), das mittels seiner exklusiv im Besitz befindlichen und patentierten Technologie therapeutische Proteine entwickelt, produziert und patentiert, die eine längere Lebensdauer besitzen und im Vergleich zu anderen Proteinprodukten seines Gleichen suchen.
Diese Produkte zielen auf den therapeutischen Proteinmarkt ab, der durch eine äußerst starke Nachfrage in den USA und Europa bekannt ist. Im Jahr 2005 kletterten die Verkaufseinnahmen in diesem Markt bereits auf $53 Mrd. an.

-------------------------

CHART USA


Mitte Mai 2007, direkt nach dem Börsengang von Modigene, wurde eine erfolgreich abgeschlossene Privatplatzierung an Wertpapieren bekannt gegeben, die Einnahmen von knapp $10 Mio. generierte, welche Mittel ausreichen dürften, die finalen Phasen der klinischen Tests und Produktzulassungen abzuschließen.

Die private Platzierung der Aktien fand zum Emissionskurs von $1,50 statt, währendhingegen die Warrants (Kaufoptionen von weiteren Aktien) zu einem Preis von $2,50 fixiert wurden und erst in 5 Jahren ausgeübt werden können. Das gesamte Management inklusive Mitglieder des Aufsichtsrats sowie 5% der Gesamtaktionäre haben eine Vereinbarung unterschrieben, ihre Wertpapiere nicht innerhalb der nächsten 18 Monate zu verkaufen. Dies zeigt deutlich, was das Management von Modigene hält und was es für die nächsten Monate und Jahre von diesem jungen (3 Wochen alt) Unternehmen erwartet (das allerdings bereits in einem fortgeschrittenen Stadium in der Entwicklung und Zulassung seiner Produkte steht).

[BikiniAnalyst]

Die einzigartige Technologie von Modigene wurde von führenden Wissenschaftlern der Washington University in St. Louis, Missouri (USA), entwickelt und basieren auf der kurzen Aminosäuren-Sequenz namens CPT (“Carboxyl Terminal Peptide”). Diese CPT kommen im menschlichen Körper vor und wenn diese mit einem therapeutischen Protein zusammengefügt werden, so verlängert sich die Lebensdauer des Proteins im menschlichen Körper, so dass es dort längere Zeit effektiv wirken kann. Dies wurde von der Firma Organon International Inc. nachgewiesen und verifiziert.

Die CPT-Technologie befindet sich derzeit in der Phase 3 (klinische Tests am Menschen), so dass die vorherigen, langatmigen Phasen bereits erfolgreich abgeschlossen wurden und somit das Risiko und hoher Kapitaleinsatz bereits Vergangenheit sind, und der Zulassungserfolg praktisch vor der Tür steht – so dass aus der Sicht eines Anlegers die
lukrativsten Zeiten praktisch vor der Tür stehen.

Modigene besitzt eine exklusive Lizenz von der Washington University für alle Proteine (außer vier endokrine Proteine, welche an Organon lizenziert wurden). Der Pharmakonzern Schering-Plough kaufte am 13. März 2007 Organon für $14,4 Mrd. Modigene ist erst seit Mitte Mai 2007 börsengelistet, so dass Modigene mit seinen Lizenzen gar nicht aufgekauft werden konnte und mittels der starken und vom Management kontrollierten Aktionärsstruktur wohl auch nicht (feindlich) übernommen werden kann.

---------------------------------------





http://www.modigeneinc.com/Technology.html

Die Ziele von Modigene mittels der Anwendung der CPT-Technologie sind wie folgt:

· Die Häufigkeit der benötigten Injektionen
an Patienten (auf revolutionäre
Weise) zu reduzieren.

· Neue Versionen von existierenden
Therapien zu entwickeln und zu patentieren.

· Bei neuen therapeutischen Proteinen
eine schnellere Vermarktung mit
weniger Risiken und Kosten zu erreichen.

· Therapeutische Proteine effizient und
nach den neusten Standards zu produzieren.

Modigene hat bereits mit der Entwicklung von 4 Produkten begonnen, die allesamt auf einen etwa $20 Mrd. großen Markt abzielen. Es konnten bereits die vorklinischen Studien an Tieren abgeschlossen werden, wo u.a. verifiziert worden ist, dass eine einzige Injektion den gleichen Effekt wie 7 bis 10 Injektionen mit herkömmlichen Mitteln hat - ohne negative Nebenwirkungen oder Effizienzeinbußen!

Darüberhinaus konnte verifiziert werden, dass der biologische Effekt höher und wesentlich länger anhält als das so hoch gepriesene Produkt von Amgen Inc., die mit ihren „langlebigen“ Proteinen Verkaufseinnahmen von $4,1 Mrd. im Jahr 2005 generieren konnten.

[BikiniAnalyst]

MANAGEMENT

Das hochkarätige Management, das sich mittlerweile unter dem Dach von Medigene zusammengefunden hat, ist in der Branche allseits bekannt und konnte in der Vergangenheit bereits außergewöhnliche Erfolge feiern, wie z.B. Dr Abraham Havron (CEO), der für Merck Serono S.A. ein Multiple-Sklerose Medikament entwickelte und Merck bisher etwa $1,3 Mrd. einbringen konnte. Ferner entwickelte er auch ein bahnbrecherisches Hepatitis-B Impfungsmittel neben anderen bereits im Markt verfügbaren Medikamenten.
http://www.modigeneinc.com/AbrahamHavronMT.html

Dass Modigene die Meisterleistung erbringen konnte, sich die revolutionierende CPT Technologie direkt von der Washington University zu lizenzieren, hat enormes Aufsehen in der Branche bewirkt.

Es ist nur allzu verständlich, dass diese Lizenzen nun die besten Köpfe der Biotechnologie-Industrie anziehen, und so konnte
beispielsweise Mitte Mai 2007 verkündet werden, dass u.a. der bekannte Dr. Philip Frost nun im Aufsichtsrat von Modigene sitzt und selber auch neben der kürzlich stattgefundenen Privatplatzierung von etwa $10 Mio. in Modigene investiert hat.
Dr. Frost ist der ehemalige CEO & Vorstandsvorsitzende von IVAX Corp., welches Unternehmen 2006 für $7,4 Mrd. an Teva Pharmaceuticals verkauft wurde, und wo Dr. Frost mittlerweile als Vize-Vorstandsvorsitzender im Aufsichtsrat sitzt. Darüberhinaus ist Dr. Frost der CEO & Vorstandsvorsitzende von Opko Health Inc. (vorher Exegenics Inc) und Direktor von Northrop Grumman Corp. Im Jahr 2006 stand Dr Frost auf der Forbes Liste der reichsten Menschen der Welt auf Platz 645.

Die “ehemalige” Kollegin von Philip Frost, Dr Jane Hsiao (vormals Vize-Vorstandsvorsitzende für technische Angelegenheiten und CTO („Chief Technical Officer“) bei IVAX zwischen 1995 und 2006) sitzt nun ebenfalls im Aufsichtsrat von Modigene und investierte in das Unternehmen. Dr Hsiao war zwischen 1998 und 2006 auch
Vorstandsvorsitzende und Präsidentin von DVM Pharmaceuticals. Sie ist derzeit Direktorin der börsengelisteten Unternehmen Protalix BioTherapeutics Inc. und Opko Health Inc. Dr Hsiao besitzt darüberhinaus HSU Investments Ltd. und ist Großaktionärin vom
Charles Hsiao Family Trust-A und –B. Dr. Frost konnte daneben auch seine ehemaligen Kollegen aus der Zeit bei IVAX CORP, Steve Rubin (ehemaliger Senior Vize-Präsident und Chefsyndikus von IVAX) und Dr. Rao Uppaluri (ehemaliger Vize-Präsident der Strategischen Planung bei IVAX), überzeugen, ebenfalls in Modigene zu investieren.

------------------------------------


Hier mal der Chart von Opko Health Inc - Da ist Philip Frost CEO und Vorstandsvorsitzender!!






STEHT MODIGENE EINE ÄHNLICHE ENTWICKLUNG BEVOR ?????

[BikiniAnalyst]

Aktuell notiert die Aktie in den USA bei $2,20 und ist somit mit $93 Mio. bewertet. Bei einer Marktbewertung von $1 Mrd. würde die Aktie bereits bei $23 stehen.

"Modigene besitzt eine exklusive Lizenz von der Washington University für alle Proteine (außer vier endokrine Proteine, welche an Organon lizenziert wurden). Der Pharmakonzern Schering-Plough kaufte am 13. März 2007 Organon für $14,4 Mrd. Modigene ist erst seit Mitte Mai 2007 börsengelistet, so dass Modigene mit seinen Lizenzen gar nicht aufgekauft werden konnte und mittels der starken und vom Management kontrollierten Aktionärsstruktur wohl auch nicht (feindlich) übernommen werden kann."

[BikiniAnalyst]

Also dieser Philip Frost ist CEO und Vorstandsvorsitzender von Opkp Health (400% Chart siehe Posting 3 !!) und gleichzeitig sitzt er auch im Aufsichtsrat von MODIGENE!

Also wenn das mal kein gutes Zeichen ist!!

[cyba]

Antwort auf Beitrag Nr.: 30.014.224 von BikiniAnalyst am 19.06.07 10:28:12

Dr. Frost ist immer ein gutes zeichen

[Peederwoogn2]

Antwort auf Beitrag Nr.: 30.014.155 von BikiniAnalyst am 19.06.07 10:24:29

mann sollte sich fragen warum die so billig für 1,50 $ an die börse gebracht wurden

[Peederwoogn2]

Antwort auf Beitrag Nr.: 30.013.453 von BikiniAnalyst am 19.06.07 09:45:33

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


--------------------------------------------------------------------------------


FORM 8-K


--------------------------------------------------------------------------------



CURRENT REPORT
Pursuant to Section 13 and 15(d) of the
Securities Exchange Act of l934

May 21, 2007 (May 21, 2007)
Date of report (Date of earliest event reported)


--------------------------------------------------------------------------------



Modigene Inc.
(Exact Name of Registrant as Specified in Its Charter)


--------------------------------------------------------------------------------


Nevada
(State or Other Jurisdiction of Incorporation)


333-136424 20-0854033
(Commission File Number) (IRS Employer Identification No.)


8000 Towers Crescent Drive, Suite 1300, Vienna, Virginia 22182
(Address of Principal Executive Offices) (Zip Code)

[phone]
(Registrant’s Telephone Number, Including Area Code)
_____________________________________________
(Former Name or Former Address, if Changed Since Last Report)



--------------------------------------------------------------------------------


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





--------------------------------------------------------------------------------







EXPLANATORY NOTE

This Current Report contains summaries of the material terms of various agreements executed in connection with the transactions described herein. The summaries of these agreements are subject to, and are qualified in their entirety by, reference to these agreements, all of which are incorporated herein by reference.

This current report responds to the following items on Form 8-K:

Item 3.02 Unregistered Sales of Equity Securities



--------------------------------------------------------------------------------





I tem 3.02 Unregistered Sales of Equity Securities

As disclosed in a Current Report on Form 8-K filed by the Modigene Inc., a Nevada corporation (the “ Company ”) on May 14, 2007 (the “ May 14 Current Report ”), on May 9, 2007 the Company closed a private placement offering (the “ Offering ”) in the initial amount of 6,418,808 units of its securities (“ Units ”) to accredited investors, as defined under Regulation D, Rule 501(a) promulgated by the Securities and Exchange Commission (the “ SEC ”). The Units were sold at a price of $1.50 per Unit, each Unit consisting of one share of common stock of the Company, par value $0.00001 per share (“ Common Stock ”) and a warrant (the “ Investor Warrants ”) to purchase one-quarter, or 25%, of a share of Common Stock for a period of five years at an exercise price of $2.50 per whole share of Common Stock. At the initial closing of the Offering, the Company raised total cash consideration of $9,628,212.

As disclosed in the May 14 Current Report, the Company had the right to raise additional funds in the Offering, up to an aggregate of $13,000,000, and expected to close on any additional funds as soon as the subscription materials (including final clearance of funds) were complete. On May 21, 2007, the Company completed this second phase of Offering and closed on the sale of an additional 2,247,858 Units, for total cash proceeds of $3,371,787.

The Offering was exempt from registration under Section 4(2) of the Securities Act of 1933, as amended (the “ Securities Act ”) and Rule 506 of Regulation D as promulgated by the SEC.

The Company agreed to pay certain broker/dealers who introduced investors in the offering a commission of up to 8.5% of the funds raised from such investors in the Offering. In addition, those broker/dealers are entitled to warrants to purchase a number of shares of Common Stock equal to 5% of the Units sold to investors introduced by them in the Offering. Pursuant to these agreements, in connection with the May 21, 2007 sales of securities, the Company has agreed to pay up to $107,600 in cash commissions, and to issue warrants to purchase up to 51,885 shares of Common Stock, to broker/dealers who assisted with the Offering.

In addition, upon the completion of the second closing of the Offering, the Company agreed to issue an additional 155,673 shares of Common Stock (for no additional consideration) to the four strategic investors participating in the private sale (the “ Private Sale ”) described in the Current Report on Form 8-K filed April 16, 2007 and as further described in the May 14 Current Report. These securities were issued to accredited investors as defined under Regulation D, Rule 501(a) promulgated by the SEC, and otherwise in accordance with the provisions of Regulation D. No underwriter was involved in the Private Sale and accordingly, there were no underwriting discounts involved.



--------------------------------------------------------------------------------






SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MODIGENE INC.
(Registrant)
Date: May 21, 2007 By: /s/ Shai Novik
Name: Shai Novik
Title: President

[BikiniAnalyst]

Benutzername: Peederwoogn2

Angaben zur Person
Ich suche: Wein, Weib und Gewinne
Ich biete: Eine Fahrt im Peederwoogn über die Alpen
Andere Interessen: Astra trinken in einschlägigen Hamburger Kneipen

------------------------------


Alles klar

[BikiniAnalyst]

ist es besser eine company günstig an die börse zu bringen, damit anschließend der kurs steigt

oder

ist es besser eine company überteuert an die börse zu bringen damit der kurs fällt ?



Einfach mal Opko ansehen



auch eine solide Aufwärtsbewegung

[Peederwoogn2]

Antwort auf Beitrag Nr.: 30.015.243 von BikiniAnalyst am 19.06.07 11:20:21

ja das bin ich

[BikiniAnalyst]

Antwort auf Beitrag Nr.: 30.015.344 von Peederwoogn2 am 19.06.07 11:25:16

wieviele Astras hast denn heute schon drin ?

[BikiniAnalyst]

Modigene Announces Completion of Second and Final Closing of Private
Placement, Bringing Total Private Placement Proceeds to $13 million

http://www.modigeneinc.com/News%5CModigeneCompletesFinalClos…

VIENNA, VA May 22, 2007
Modigene Inc., a Nevada corporation (OTCBB: MODG), a therapeutically driven biopharmaceutical company focused on the development and commercialization of long-acting versions of approved therapeutic proteins which address an existing combined market of more than $20 billion, today announced the completion of the second and final closing of its private placement, bringing total gross proceeds in the private placement to approximately $13 million, and $15 million overall. As disclosed in a report on Form 8-K filed by the Modigene on May 14, 2007, Modigene issued 6,418,808 shares for a total of 9,628,212 million, and 1,604,702 warrants in the first closing of the private placement. With the additional $2 million investment from Dr. Frost, Dr. Hsiao, Mr. Rubin and Dr. Uppaluri, total gross proceeds were approximately $11.6 million. The warrants expire five years from issuance, and have an exercise price of $2.50. In addition, Modigene had the right to raise additional funds in the private placement, up to an aggregate of $13 million, such that with the additional $2 million investment from Dr. Frost, Dr. Hsiao, Mr. Rubin and Dr.
Uppaluri, total gross proceeds would approximately be $15 million, and expected to close on any such additional funds as soon as the investor subscription materials (including final clearance of funds) were complete. On May 21, 2007, the Company completed this procedural second and final phase of the private placement and closed on the sale of an additional 2,247,858 shares and 561,965 warrants, of the same terms as issued in the first closing, for total additional cash
proceeds of $3,371,787.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 30.015.435 von BikiniAnalyst am 19.06.07 11:29:28

ich trinke erst ab 18 h

[BikiniAnalyst]

und hier noch die ganzen restlichen News:



Modigene Announces Closing of Merger and $9.6 Million Private Placement, Appointment of Dr. Phillip Frost and Dr. Jane Hsiao to its Board of Directors
May 15, 2007
http://www.modigeneinc.com/News%5CNewsMergerampFundingMay200…


Modigene Announces Signing of Exclusive CTP Definitive License
Expansion Agreement With Washington University in St. Louis
February 15, 2007
http://www.modigeneinc.com/News%5CNewsWashLicenseExpansion.p…

Modigene Announces Approval Of Grant Awarded By The Israeli Office
Of The Chief Scientist To Its R&D Subsidiary, ModigeneTech Ltd.
September 27, 2006
http://www.modigeneinc.com/News%5CNewsOCSApprovalSep06.pdf

Modigene Announces Appointment of Bexxar®, Mylotarg®, and CEAScan
® Developer to its Scientific Advisory Board
March 1, 2006
http://www.modigeneinc.com/News%5CDrDanShochatjoinsSAB.pdf

Modigene Announces Three New Appointments to its Scientific
Advisory Board
February 1, 2006
http://www.modigeneinc.com/News%5CSAB.pdf

Modigene Announces Signing of License Expansion Agreement With
Washington University in St. Louis
December 27, 2005
http://www.modigeneinc.com/News%5CWashULicenseExpansion.pdf

Modigene Appoints Co-Developer of Five Therapeutic Proteins as Chief
Executive Officer
December 14, 2005
http://www.modigeneinc.com/News%5CAbrahamHavronAppointedCEO.…

Modigene Announces Closing of $3 Million Funding
December 14, 2005
http://www.modigeneinc.com/News%5C3MillionFunding.pdf

Modigene Appoints Dr. Eugene Bauer as Chairman of the Board of
Directors, Dr. Alastair Clemow as Member of the Board of Directors
June 10, 2005
http://www.modigeneinc.com/News%5CEugeneBauerAppointedChairm…

[BikiniAnalyst]

http://www.modigeneinc.com/FactSheet%5CModigeneCorporateFact… (es öffnet sich ein pdf)

[BikiniAnalyst]

Therapeutic proteins are proteins that are either extracted from human cells or engineered in the laboratory for pharmaceutical use. The majority of therapeutic proteins are recombinant human proteins manufactured using non-human mammalian cell lines that are engineered to express certain human genetic sequences to produce specific proteins. Recombinant proteins are an important class of therapeutics used to replace deficiencies in critical blood borne growth factors and to strengthen the immune system to fight cancer and infectious disease. Therapeutic proteins are also used to relieve patients' suffering from many conditions, including various cancers (treated by monoclonal antibodies and interferons), heart attacks, strokes, cystic fibrosis and Gaucher's disease (treated by Enzymes and blood factors), diabetes (treated by insulin), anemeia (treated by erythopoietins), and hemophilia (treated by blood clotting factors).



The FDA has approved 75 therapeutic proteins, also known as biopharmaceuticals, and there are more than 500 additional proteins under development. Worldwide sales of therapeutic proteins were reported to be approximately $53 billion in 2005, and are expected to increase to more than $70 billion by 2008. To date, most of the growth has been in sales of erythopoietins (used to treat anemia) and insulins (used to treat diabetes). Many of the proteins currently on the market will lose the protection of certain patent claims over the next 15 years. In addition, many marketed proteins are facing increased competition from next-generation versions or from other therapeutic proteins approved for the same disease indications.

Because proteins are broken down in the gastrointestinal system, marketed therapeutic proteins must be administered by injection. Once in the bloodstream, therapeutic proteins are broken down by enzymes and cellular activity, as well as filtered out of the blood by the body's organs. Therefore, injections must be given frequently to achieve effective therapeutic levels.

[BikiniAnalyst]

The chance of a new drug under development that successfully passed animal models experiments to reach FDA approval is 1 in 100. It is still only 1 in 10 for the same new drug after it successfully passes Phase I human clinical trials.

It is very costly, lengthy and risky to develop new drugs. The inherent risk/reward trade-off of developing improved versions of existing drugs is fundamentally superior to that of new drug development efforts. This is the strong economic rationale behind Modigene`s business strategy.

[BikiniAnalyst]

We believe that the CTP technology will be broadly applicable to many of the best-selling therapeutic proteins in the market and will be attractive to potential partners because it will allow them to extend proprietary rights for therapeutic proteins with near-term patent expirations.

Our strategy of targeting therapeutic proteins already approved by the FDA, with proven safety and efficacy, allows us to lower the risk profile of our proprietary development portfolio compared to de novo therapeutic protein development. This will increase the ease of therapeutic protein development because modifying an existing therapeutic protein is significantly easier and less risky than developing a new one. This strategy should also lead to less expensive, faster clinical trials since endpoints and study protocols will be the same as those used for existing therapies.

[BikiniAnalyst]

Hier alle SEC-Filings von Modigene!

http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CI…

[BikiniAnalyst]

http://www.forbes.com/lists/2006/10/RT14.html

The World's Billionaires

[BikiniAnalyst]

http://www.bloomberg.com/apps/news?pid=10000103&sid=a3mkJLeP…

Bill Gates Tops Forbes List of Billionaires for the 12th Year

By Heather Burke

March 9 (Bloomberg) -- Microsoft Corp. Chairman Bill Gates's net worth has risen to $50 billion, making him the world's richest person and widening his lead over No. 2 Warren Buffett, according to Forbes magazine's annual survey.

Gates's fortune increased 7.5 percent from $46.6 billion last year, while Buffett, 75, chairman of Berkshire Hathaway Inc., lost 4.8 percent to $42 billion. Gates, 50, has been at the top of the Forbes list for the last 12 years.

The rest of the top five were all from outside the U.S.: Mexico's Carlos Slim Helu, 66, whose companies include mobile- telephone carrier America Movil SA, rose to third from fourth, at $30 billion. Sweden's Ingvar Kamprad, 79, founder of Ikea, the world's biggest home furnishings retailer, jumped to fourth from sixth, with $28 billion; and India's Lakshmi Mittal, 55, chairman of Mittal Steel Co., fell to fifth from third, at $23.5 billion.

The magazine counted 793 billionaires around the globe, with a total net worth of $2.6 trillion, up 18 percent from last year largely because of strong stock performance, Forbes said.

New members of the billionaires' club include Christy Walton, 51, in 17th place, with a fortune of $15.9 billion. Her husband, John Walton, who died in a plane crash in 2005, was the son of Wal-Mart Stores Inc. founder Sam Walton.

Martha Stewart, who joined the billionaire ranks last year with a net worth of $1 billion, is no longer on the list. She was one of 39 who fell out of this year's compilation, Forbes said.

Top 10

Among the rest of the top 10, Microsoft co-founder Paul Allen, 53, moved up one spot to sixth, with a net worth of $22 billion. France's Bernard Arnault, 57, chairman of LVMH Moet Hennessy Louis Vuitton SA, the world's largest luxury-goods maker, vaulted to seventh place from 17th, with a $21.5 billion net worth.

Saudi Arabia's Prince Alwaleed bin Talal, 49, fell to eighth place from fifth, as his fortune dipped to $20 billion from $23.7 billion last year.

Toronto-based Kenneth Thomson, 82, and his family, whose Thomson Corp. owns the Westlaw legal research and First Call stock-market data service, rose to ninth place from 15th, with $19.6 billion. Hong Kong investor Li Ka-shing, 77, rose to 10th, from 22nd, with $18.8 billion.

Europe had 15 new billionaires, including Petr Kellner, 41, owner of PPF Group NV, the biggest independent financial services company in the Czech Republic. Among other new billionaires were James Dyson, 58, founder of the namesake British vacuum cleaner company, and Suleiman Kerimov, 40, owner of Russian investment company OAO GNK Nafta Moskva, Forbes said.

New York Billionaires

The U.S. has the most billionaires, 371, followed by Germany at 55. New York is home to the most billionaires, with 40, followed by Moscow, at 25, and London, with 23.

Of the 793 billionaires on the list, 452 are described as self-made, meaning they didn't inherit their money. Seventy-eight are women, up from 68 in 2005, Forbes reported.

Hind Hariri, daughter of the assassinated former Lebanese Prime Minister Rafiq Hariri, was the youngest billionaire at 22. She is eight months older than Prince Albert von Thurn und Taxis of Germany.

This is a test

Forbes Magazine's List of the World's Richest People
Net
Worth
Rank Name Country ($bln) Source
1 William Gates III U.S. 50.0 Microsoft
2 Warren Buffett U.S. 42.0 Berkshire Hathaway
3 Carlos Slim Helu Mexico 30.0 telecom
4 Ingvar Kamprad Sweden 28.0 Ikea
5 Lakshmi Mittal India 23.5 steel
6 Paul Allen U.S. 22.0 Microsoft,
investments
7 Bernard Arnault France 21.5 LVMH
8 Prince Alwaleed Bin Talal Alsaud Saudi Arabia 20.0 investments
9 Kenneth Thomson & family Canada 19.6 publishing
10 Li Ka-shing Hong Kong 18.8 diversified
11 Roman Abramovich Russia 18.2 oil
12 Michael Dell U.S. 17.1 Dell
13 Karl Albrecht Germany 17.0 supermarkets
14 Sheldon Adelson U.S. 16.1 casinos, hotels
15 Liliane Bettencourt France 16.0 L'Oreal
15 Lawrence Ellison U.S. 16.0 Oracle
17 Christy Walton U.S. 15.9 Wal-Mart inheritance
17 Jim Walton U.S. 15.9 Wal-Mart
19 S. Robson Walton U.S. 15.8 Wal-Mart
20 Alice Walton U.S. 15.7 Wal-Mart
21 Helen Walton U.S. 15.6 Wal-Mart
22 Theo Albrecht Germany 15.2 supermarkets
23 Amancio Ortega Spain 14.8 Zara
24 Steven Ballmer U.S. 13.6 Microsoft
25 Azim Premji India 13.3 software
26 Sergey Brin U.S. 12.9 Google
27 Larry Page U.S. 12.8 Google
28 Abigail Johnson U.S. 12.5 Fidelity
29 Nasser Al-Kharafi & family Kuwait 12.4 construction
29 Barbara Cox Anthony U.S. 12.4 Cox Enterprises
29 Anne Cox Chambers U.S. 12.4 Cox Enterprises
32 Stefan Persson Sweden 12.3 Hennes & Mauritz
33 Charles Koch U.S. 12.0 oil, commodities
33 David Koch U.S. 12.0 oil, commodities
35 Raymond, Thomas & Walter Kwok Hong Kong 11.6 real estate
36 Adolf Merckle Germany 11.5 drugs
37 Sulaiman Bin Abdul Al Rajhi Saudi Arabia 11.0 banking
37 Vagit Alekperov Russia 11.0 oil
37 Silvio Berlusconi Italy 11.0 media
37 Lee Shau Kee Hong Kong 11.0 real estate
41 Vladimir Lisin Russia 10.7 steel
42 Michael Otto & family Germany 10.4 retail
43 Pierre Omidyar U.S. 10.1 Ebay
44 Leonardo Del Vecchio Italy 10.0 eyewear
44 Michele Ferrero & family Italy 10.0 chocolates
44 Forrest Mars Jr. U.S. 10.0 candy
44 Jacqueline Mars U.S. 10.0 candy
44 John Mars U.S. 10.0 candy
44 Viktor Vekselberg Russia 10.0 oil, metals
50 Mikhail Fridman Russia 9.7 oil, banking
51 Spiro Latsis & family Greece 9.1 banking
52 John Kluge U.S. 9.0 Metromedia
53 Carl Icahn U.S. 8.7 leveraged buyouts
53 Kirk Kerkorian U.S. 8.7 investments, casinos
55 Birgit Rausing & family Sweden 8.6 packaging
56 Mukesh Ambani India 8.5 petrochemicals
56 Serge Dassault & family France 8.5 aviation
56 Hans Rausing Sweden 8.5 packaging
59 Galen Weston & family Canada 8.4 retail
60 Susanne Klatten Germany 8.1 BMW
61 Rudolf August Oetker & family Germany 8.0 food
62 Oleg Deripaska Russia 7.8 aluminum
63 Sumner Redstone U.S. 7.7 Viacom
64 Alexei Mordashov Russia 7.6 steel
65 Donald Newhouse U.S. 7.5 publishing
65 Samuel Newhouse Jr. U.S. 7.5 publishing
65 Alain & Gerard Wertheimer France 7.5 Chanel
65 Reinhold Wuerth Germany 7.5 manufacturing
69 Joseph & Moise Safra Brazil 7.4 banking
70 Philip Knight U.S. 7.3 Nike
71 George Soros U.S. 7.2 hedge funds
72 Ernesto Bertarelli Switzerland 7.1 biotech
72 Suleiman Kerimov Russia 7.1 stocks
74 Philip & Cristina Green U.K. 7.0 retail
74 Francois Pinault France 7.0 retail
74 August von Finck Germany 7.0 investments
77 Mohammed Al Amoudi Saudi Arabia 6.9 oil
77 Abdul Aziz Al Ghurair & family United Arab 6.9 banking
Emirates
79 Maria-Elisabeth Germany 6.8 ball bearings
& Georg Schaeffler
80 Charles Ergen U.S. 6.7 EchoStar
80 Edward Johnson III U.S. 6.7 Fidelity
82 Kun-Hee Lee & family South Korea 6.6 Samsung
82 Stefan Quandt Germany 6.6 BMW
84 Saleh Bin Abdul Aziz Al Rajhi Saudi Arabia 6.5 banking
84 Rafael del Pino & family Spain 6.5 construction
84 Stanley Ho Hong Kong 6.5 gaming
84 Maersk Mc-Kinney Moller Denmark 6.5 shipping
84 Keith Murdoch U.S. 6.5 News Corp.
89 Philip Anschutz U.S. 6.4 investments
89 Hasso Plattner Germany 6.4 SAP
89 Vladimir Potanin Russia 6.4 metals
89 Mikhail Prokhorov Russia 6.4 metals
93 Vladimir Yevtushenkov Russia 6.3 telecom
94 Micky Arison U.S. 6.1 Carnival Cruises
94 Curt Engelhorn Germany 6.1 drugs
94 Friedrich Flick Jr. Germany 6.1 investments
94 German Khan Russia 6.1 oil, banking
94 Ronald Perelman U.S. 6.1 leveraged buyouts
94 Johanna Quandt Germany 6.1 BMW
100 Dan Duncan U.S. 6.0 energy
100 Gerald Cavendish Grosvenor U.K. 6.0 real estate
& family
100 Jack Taylor U.S. 6.0 Enterprise
Rent-A-Car
103 Eli Broad U.S. 5.9 investments
104 Anil Ambani India 5.7 diversified
104 Donald Bren U.S. 5.7 real estate
106 James, Arthur & John Irving Canada 5.5 oil
107 Yasuo Takei & family Japan 5.4 credit
107 Y.C. Wang Taiwan 5.4 chemicals
109 Shari Arison Israel 5.2 inheritance,
cruise ships
109 Kunio Busujima & family Japan 5.2 gaming
109 Nikolai Tsvetkov Russia 5.2 oil, banking
112 Michael Bloomberg U.S. 5.1 Bloomberg L.P.
112 Cheng Yu-tung Hong Kong 5.1 real estate
114 Leonard Blavatnik U.S. 5.0 Access Industries
114 Gustavo Cisneros & family Venezuela 5.0 media
114 Charlene de Carvalho-Heineken Netherlands 5.0 Heineken
114 John Fredriksen Norway 5.0 shipping
114 Saleh Kamel Saudi Arabia 5.0 diversified
114 Karl-Heinz Kipp Germany 5.0 retail
114 Robert Kuok Malaysia 5.0 diversified
114 John Menard Jr. U.S. 5.0 home improvement
stores
114 James Packer Australia 5.0 inherited
114 Kushal Pal Singh India 5.0 real estate
114 Jeffrey Skoll Canada 5.0 EBay
125 Alexander Abramov Russia 4.9 steel, mining
125 Erivan Haub & family Germany 4.9 retail
125 Lorenzo Mendoza & family Venezuela 4.9 beverages
125 Sunil Mittal India 4.9 telecom
129 Alexei Kuzmichov Russia 4.8 oil, banking
129 Robert Rowling U.S. 4.8 oil & gas,
investments
129 Onsi Sawiris Egypt 4.8 Orascom Telecom
129 Eric Schmidt U.S. 4.8 Google
133 Nobutada Saji & family Japan 4.7 beverages
134 Jeronimo Arango Mexico 4.6 retail
134 Nicky Oppenheimer & family South Africa 4.6 De Beers
136 Iskander Makhmudov Russia 4.5 mining, metals
136 Akira Mori & family Japan 4.5 real estate
136 Julio Mario Santo Domingo Colombia 4.5 beer, diversified
136 Shin Kyuk-Ho & family South Korea 4.5 candy
140 Kumar Birla India 4.4 commodities
140 David Geffen U.S. 4.4 DreamWorks
140 Steven Jobs U.S. 4.4 Apple Computer,
Pixar
140 George Kaiser U.S. 4.4 oil & gas, banking
140 Luis Carlos Sarmiento Colombia 4.4 banking
140 Thomas Schmidheiny Switzerland 4.4 cement
140 H. Ty Warner U.S. 4.4 Beanie Babies
147 Jeffrey Bezos U.S. 4.3 Amazon
147 Terry Gou Taiwan 4.3 technology
147 Walter Haefner Switzerland 4.3 software
147 Charles Johnson U.S. 4.3 Franklin Resources
147 Ananda Krishnan Malaysia 4.3 diversified
147 Reinhard Mohn & family Germany 4.3 media
147 Henry Perot U.S. 4.3 investments
154 Jean-Claude Decaux & family France 4.2 advertising
154 Eitaro Itoyama Japan 4.2 golf courses
154 Nina Wang Hong Kong 4.2 real estate
154 Tadashi Yanai & family Japan 4.2 retail
158 Giorgio Armani Italy 4.1 fashion
158 Vladimir Bogdanov Russia 4.1 oil
158 Lester Crown & family U.S. 4.1 investments
158 James Goodnight U.S. 4.1 SAS Institute
158 Bahaa Hariri Switzerland 4.1 inheritance
158 Saad Hariri Saudi Arabia 4.1 construction,
investments
158 Antonia Johnson Sweden 4.1 diversified
158 Klaus-Michael Kuehne Germany 4.1 shipping
158 Eliodoro Matte & family Chile 4.1 paper
158 Richard Schulze U.S. 4.1 Best Buy
168 Leonid Fedun Russia 4.0 oil
168 David Murdock U.S. 4.0 investments
168 Shiv Nadar India 4.0 technology
168 Madeleine Schickedanz Germany 4.0 retail
168 Charles Schwab U.S. 4.0 discount stock
brokerage
173 Boris Ivanishvili Russia 3.9 steel, banking
174 Abdullah Al Rajhi Saudi Arabia 3.8 banking
174 Paul Desmarais Canada 3.8 finance
174 Aloysio de Andrade Faria Brazil 3.8 banking
174 Michael Kadoorie & family Hong Kong 3.8 diversified
174 Frank Lowy & family Australia 3.8 malls
174 Ng Teng Fong Singapore 3.8 real estate
174 James Sorenson U.S. 3.8 medical devices,
real estate
181 Anacleto Angelini Chile 3.7 energy
181 Henry Fok Hong Kong 3.7 gaming
181 Gordon Moore U.S. 3.7 Intel
181 Bernard (Barry) Sherman Canada 3.7 drugs
185 Masatoshi Ito Japan 3.6 retail
185 Rupert Johnson Jr. U.S. 3.6 Franklin Resources
185 Kwek Leng Beng & family Singapore 3.6 hotels
185 Ralph Lauren U.S. 3.6 fashion
185 Pallonji Mistry India 3.6 construction
185 Viktor Rashnikov Russia 3.6 iron, steel
185 David & Simon Reuben U.K. 3.6 investments, real
estate
185 Andreas Struengmann Germany 3.6 generic drugs
185 Thomas Struengmann Germany 3.6 generic drugs
194 William Davidson U.S. 3.5 glass
194 Bradley Hughes U.S. 3.5 Public Storage
194 Edward Lampert U.S. 3.5 investments
194 Alexander Lebedev Russia 3.5 stocks
194 George Lucas U.S. 3.5 Star Wars
194 Jim Pattison Canada 3.5 diversified
200 Robert Bass U.S. 3.4 oil, investments
200 Otto Beisheim Germany 3.4 retail
200 Richard DeVos U.S. 3.4 Alticor
200 Bernard Ecclestone & family U.K. 3.4 Formula One
200 Esther Koplowitz Spain 3.4 construction
200 Jorge Paulo Lemann Brazil 3.4 banking
200 Gerard Louis-Dreyfus & family France 3.4 commodities
207 Chung Mong-Koo & family South Korea 3.3 Hyundai
207 Anurag Dikshit India 3.3 online gambling
207 Johann Rupert & family South Africa 3.3 luxury goods
207 Rainer & Michael Germany 3.3 retail
Schmidt-Ruthenbeck
207 Tsai Wan Tsai & family Taiwan 3.3 banking
207 Klaus Tschira Germany 3.3 SAP
207 Karl Wlaschek Austria 3.3 department stores
214 Khalid Bin Mahfouz & family Saudi Arabia 3.2 banking
214 Martin Bouygues & family France 3.2 telecom
214 William Cook U.S. 3.2 medical devices
214 Antonio Ermirio de Moraes Brazil 3.2 diversified
& family
214 Yoshitaka Fukuda & family Japan 3.2 credit
214 Maurice Greenberg U.S. 3.2 insurance
214 Charoen Sirivadhanabhakdi Thailand 3.2 alcohol
221 Ricardo Salinas Pliego & family Mexico 3.1 retail, media
221 Stephan Schmidheiny Switzerland 3.1 investments
221 Masayoshi Son Japan 3.1 Softbank
224 Gianluigi & Rafaela Aponte Switzerland 3.0 shipping
224 Roland Arnall U.S. 3.0 mortgage banking
224 Pyotr Aven Russia 3.0 oil, banking
224 Edgar Bronfman Sr. U.S. 3.0 liquor
224 Albert Frere Belgium 3.0 investments
224 Frits Goldschmeding Netherlands 3.0 temp agency
224 Heidi Horten Austria 3.0 department stores
224 Petr Kellner Czech 3.0 insurance
Republic
224 Lee Seng Wee & family Singapore 3.0 banking
224 Hiroshi Mikitani Japan 3.0 e-commerce
224 Robert Miller Canada 3.0 Future Electronics
224 Sammy Ofer & family Israel 3.0 shipping
224 Edward Rogers Canada 3.0 media
224 Anton Schlecker Germany 3.0 retail
224 Takemitsu Takizaki Japan 3.0 sensors
224 William Wrigley Jr. U.S. 3.0 chewing gum
240 David Filo U.S. 2.9 Yahoo
240 Michael Herz Germany 2.9 coffee
240 Leonard Lauder U.S. 2.9 Estee Lauder
240 Arnon Milchan Israel 2.9 New Regency
240 A. Jerrold Perenchio U.S. 2.9 Univision
245 Anil Agarwal India 2.8 mining, metals
245 Alberto Bailleres Mexico 2.8 mining
245 David & Frederick Barclay U.K. 2.8 media, retail
245 Richard Branson U.K. 2.8 Virgin
245 Charles Cadogan & family U.K. 2.8 real estate
245 Wolfgang Herz Germany 2.8 coffee
245 Kjeld Kirk Kristiansen Denmark 2.8 Lego
245 Lim Goh Tong Malaysia 2.8 gaming
245 Carl Pohlad U.S. 2.8 banking
245 Ravi & Shashi Ruia India 2.8 diversified
245 Haim Saban U.S. 2.8 television
245 Stefan Schoerghuber Germany 2.8 real estate
245 Steven Spielberg U.S. 2.8 movies
258 John Abele U.S. 2.7 Boston Scientific
258 Charles Bronfman Canada 2.7 liquor
258 Matthew Bucksbaum & family U.S. 2.7 real estate
258 John Calamos U.S. 2.7 mutual funds
258 Francesco Gaetano Caltagirone Italy 2.7 diversified
258 Jesus de Polanco Spain 2.7 media
258 Otto Happel Germany 2.7 engineering
258 Ayman Hariri Saudi Arabia 2.7 inheritance
258 Fahd Hariri Lebanon 2.7 inheritance
258 Henry Hillman U.S. 2.7 industrialist
258 Martha Ingram & family U.S. 2.7 Ingram Industries
258 Manuel Jove Spain 2.7 real estate
258 Vladimir Kim Kazakhstan 2.7 mining
258 Ronald Lauder U.S. 2.7 Estee Lauder
258 Andrei Melnichenko Russia 2.7 banking, energy
258 Henry Nicholas III U.S. 2.7 Broadcom
258 Sergei Popov Russia 2.7 banking, energy
258 Leonard Stern U.S. 2.7 real estate
258 Leslie Wexner U.S. 2.7 Limited Brands
258 Michael Ying Hong Kong 2.7 Esprit
278 Chen Din Hwa Hong Kong 2.6 real estate
278 Adi Godrej & family India 2.6 diversified
278 Barbara Piasecka Johnson U.S. 2.6 inheritance
278 Peter Kellogg U.S. 2.6 investments
278 Ann Walton Kroenke U.S. 2.6 Wal-Mart
278 Lev Leviev Israel 2.6 diamonds
278 Hugo Mann & family Germany 2.6 retail
278 Naguib Sawiris Egypt 2.6 Orascom Telecom
278 Harold Simmons U.S. 2.6 investments
278 Melvin Simon U.S. 2.6 real estate
278 James Simons U.S. 2.6 hedge funds
278 John Simplot & family U.S. 2.6 potatoes, microchips
278 Donald Trump U.S. 2.6 real estate
278 Alisher Usmanov Russia 2.6 steel
292 Riley Bechtel U.S. 2.5 engineering
292 Stephen Bechtel Jr. U.S. 2.5 engineering
292 Carlo Benetton Italy 2.5 Benetton
292 Gilberto Benetton Italy 2.5 Benetton
292 Giuliana Benetton Italy 2.5 Benetton
292 Luciano Benetton Italy 2.5 Benetton
292 Steven Cohen U.S. 2.5 hedge funds
292 Barbara Davis & family U.S. 2.5 inheritance, oil
292 John Dorrance III Ireland 2.5 Campbell Soup
292 Jean-Louis Dumas & family France 2.5 Hermes
292 Nicolas Hayek Switzerland 2.5 Swatch
292 Ray Hunt U.S. 2.5 oil, real estate
292 Fukuzo Iwasaki Japan 2.5 real estate
292 Bruce Kovner U.S. 2.5 hedge funds
292 Henry Kravis U.S. 2.5 leveraged buyouts
292 Leonid Mikhelson Russia 2.5 natural gas
292 Miuccia Prada & family Italy 2.5 Prada
292 Sean Quinn & family Ireland 2.5 real estate,
insurance
292 J. Ricketts & family U.S. 2.5 Ameritrade
292 George Roberts U.S. 2.5 leveraged buyouts
292 David Rockefeller Sr. U.S. 2.5 Standard Oil,
banking
292 Bruno Schroder & family U.K. 2.5 banking
292 Stephen Schwarzman U.S. 2.5 investments
292 Dennis Washington U.S. 2.5 construction, mining
292 Chaleo Yoovidhya Thailand 2.5 Red Bull
317 Clive Calder U.K. 2.4 record label
317 Dhanin Chearavanont & family Thailand 2.4 agriculture
317 Stein Erik Hagen Norway 2.4 supermarkets
317 Indu Jain India 2.4 media
317 Richard Kinder U.S. 2.4 pipelines
317 Sergio Mantegazza Switzerland 2.4 travel
317 Dietrich Mateschitz Austria 2.4 Red Bull
317 George Mitchell U.S. 2.4 Mitchell Energy
317 Axel Oberwelland Germany 2.4 candy
317 Didier Primat France 2.4 oil
317 Henry Samueli U.S. 2.4 Broadcom
317 Emanuele (Lino) Saputo & family Canada 2.4 dairy
317 Dilip Shanghvi India 2.4 pharmaceuticals
317 Steven Udvar-Hazy U.S. 2.4 leasing
317 Wee Cho Yaw Singapore 2.4 banking
317 Stef Wertheimer & family Israel 2.4 tools
317 Jerry Yang U.S. 2.4 Yahoo
317 Samuel Zell U.S. 2.4 real estate
335 Khalaf Al Habtoor United Arab 2.3 construction
Emirates
335 Mohammed Al Issa Saudi Arabia 2.3 food
335 Elena Baturina Russia 2.3 construction
335 Hubert Burda Germany 2.3 publishing
335 Ronald Burkle U.S. 2.3 investments
335 Alexander Frolov Russia 2.3 mining, steel
335 Wallace McCain Canada 2.3 food
335 Peter Nicholas U.S. 2.3 Boston Scientific
335 Richard Pratt Australia 2.3 packaging
335 Richard Rainwater U.S. 2.3 investments
335 Hermann Schnabel Germany 2.3 chemicals
335 Yasumitsu Shigeta Japan 2.3 telecom
335 Clemmie Spangler Jr. U.S. 2.3 investments
335 Friede Springer Germany 2.3 publishing
335 Peter Woo & family Hong Kong 2.3 real estate
350 Bjorgolfur Thor Bjorgolfsson Iceland 2.2 diversified
350 Charles Butt U.S. 2.2 supermarkets
350 Belmiro de Azevedo Portugal 2.2 diversified
350 John de Mol Netherlands 2.2 TV
350 Ennio Doris & family Italy 2.2 insurance
350 Gordon Getty U.S. 2.2 inheritance, oil
350 Leona Mindy Rosenthal Helmsley U.S. 2.2 real estate
350 Amos Hostetter Jr. U.S. 2.2 cable television
350 Nancy Walton Laurie U.S. 2.2 Wal-Mart
350 Carl Lindner Jr. & family U.S. 2.2 investments
350 Bernard Marcus U.S. 2.2 Home Depot
350 Rosalia Mera Spain 2.2 Zara
350 Mario Moretti Polegato Italy 2.2 shoes
350 Mitchell Rales U.S. 2.2 Danaher Corp.
350 Shi Zhengrong Australia 2.2 solar energy
365 Mohammed Al Rajhi Saudi Arabia 2.1 banking
365 Heinz-Horst Deichmann Germany 2.1 shoes
365 H. Huizenga U.S. 2.1 investments
365 Herbert Kohler & family U.S. 2.1 plumbing fixtures
365 Michael Lee-Chin Canada 2.1 mutual funds
365 Fredrik Lundberg Sweden 2.1 real estate,
investments
365 Alfred Mann U.S. 2.1 inventor,
entrepreneur
365 Craig McCaw U.S. 2.1 McCaw Cellular
365 Ernest Rady U.S. 2.1 banking, insurance
365 Steven Rales U.S. 2.1 Danaher Corp.
365 Evgeny (Eugene) Shvidler U.S. 2.1 oil
365 Frederick Smith U.S. 2.1 FedEx
365 Glen Taylor U.S. 2.1 printing
365 Teh Hong Piow Malaysia 2.1 banking
365 Patrick Wang & family Hong Kong 2.1 micromotors
365 Cher Wang & Wenchi Chen Taiwan 2.1 technology
365 Stephen Wynn U.S. 2.1 casinos, hotels
382 Leonore Annenberg U.S. 2.0 inheritance
382 Maria Asuncion Aramburuzabala Mexico 2.0 beer
& family
382 Nadhmi Auchi U.K. 2.0 diversified
382 Charles Brandes U.S. 2.0 money management
382 Richard & Christopher Chandler New Zealand 2.0 investments
382 Patokh Chodiev Belgium 2.0 mining, metals
382 Philippe Foriel-Destezet France 2.0 temp agency
382 David Green U.S. 2.0 Hobby Lobby
382 William Hearst III U.S. 2.0 Hearst Corp.
382 Roberto Hernandez Ramirez Mexico 2.0 banking
382 Daniela Herz Germany 2.0 coffee
382 Guenter Herz Germany 2.0 coffee
382 Alijan Ibragimov Kazakhstan 2.0 mining, metals
382 Paul Jones II U.S. 2.0 hedge funds
382 Peter Lewis U.S. 2.0 Progressive Corp.
382 Alexander Machkevich Israel 2.0 mining, metals
382 Margaret Magerko U.S. 2.0 84 Lumber
382 Patrick McGovern U.S. 2.0 IDG
382 Michael Milken U.S. 2.0 investments
382 Roger Penske U.S. 2.0 cars
382 Quek Leng Chan Malaysia 2.0 banking
382 Clayton Riddell Canada 2.0 oil & gas
382 John Sall U.S. 2.0 SAS Institute
382 John Sobrato U.S. 2.0 real estate
382 Zygmunt Solorz-Zak Poland 2.0 TV station
382 Yitzhak Tshuva Israel 2.0 real estate
382 Robert E. (Ted) Turner U.S. 2.0 cable television
382 Mortimer Zuckerman U.S. 2.0 media, real estate
410 Herbert Allen Jr. U.S. 1.9 investment banking
410 Heinz Bauer Germany 1.9 publishing
410 Phoebe Hearst Cooke U.S. 1.9 Hearst Corp.
410 Louis Gonda U.S. 1.9 leasing
410 Rachman Halim & family Indonesia 1.9 tobacco
410 Austin Hearst U.S. 1.9 Hearst Corp.
410 David Hearst Jr. U.S. 1.9 Hearst Corp.
410 George Hearst Jr. U.S. 1.9 Hearst Corp.
410 Joachim Herz Germany 1.9 coffee
410 Irwin Jacobs U.S. 1.9 Qualcomm
410 S. Curtis Johnson U.S. 1.9 SC Johnson & Sons
410 Clayton Mathile U.S. 1.9 Iams
410 Thomas Pritzker U.S. 1.9 hotels, investments
410 Tamir Sapir U.S. 1.9 real estate
410 Ronda Stryker U.S. 1.9 Stryker Corp.
410 Roustam Tariko Russia 1.9 banking, vodka
410 Albert von Thurn und Taxis Germany 1.9 diversified
410 Hiroshi Yamauchi Japan 1.9 Nintendo
428 S. Daniel Abraham U.S. 1.8 Slim-Fast
428 Isak Andic Spain 1.8 textiles
428 Lee Bass U.S. 1.8 oil, investments
428 Pierre Bellon & family France 1.8 food services
428 Franklin Booth Jr. U.S. 1.8 Berkshire Hathaway
428 James Cargill U.S. 1.8 inheritance
428 Margaret Cargill U.S. 1.8 inheritance
428 Mark Cuban U.S. 1.8 Broadcast.com
428 J. DeLeon U.S. 1.8 online gaming
428 Stanley Druckenmiller U.S. 1.8 hedge funds
428 Donald Hall U.S. 1.8 Hallmark
428 R. Budi Hartono Indonesia 1.8 tobacco
428 Hans-Werner Hector Germany 1.8 SAP
428 Jess Jackson U.S. 1.8 Kendall-Jackson
428 Ruth Parasol U.S. 1.8 online gaming
428 Stefano Pessina Italy 1.8 pharmaceuticals
428 Penny Pritzker U.S. 1.8 hotels, investments
428 Fayez Sarofim U.S. 1.8 money management
428 Ernest Stempel U.S. 1.8 insurance
428 Jon Stryker U.S. 1.8 Stryker Corp.
428 Olav Thon Norway 1.8 real estate
428 Eugen Viehof & family Germany 1.8 retail
428 Lorenzo Zambrano & family Mexico 1.8 cement
451 Rinat Akhmetov Ukraine 1.7 steel, coal mines
451 Emilio Azcarraga Jean Mexico 1.7 media
451 Vincent Bollore France 1.7 investments,
inheritance
451 Emilio Botin Spain 1.7 banking
451 Charles Dolan U.S. 1.7 Cablevision Systems
451 Bennett Dorrance U.S. 1.7 inheritance
451 Gustaf Douglas Sweden 1.7 security
451 Gabriel Escarrer Spain 1.7 hotels
451 Thomas Frist Jr. & family U.S. 1.7 HCA Healthcare
451 Tetsuro Funai Japan 1.7 VCRs
451 Tom Gores U.S. 1.7 leveraged buyouts
451 Nazek Hariri Lebanon 1.7 inheritance
451 Graeme Hart New Zealand 1.7 investments
451 Vladimir Iorikh Russia 1.7 mining, steel
451 Rahmi Koc Turkey 1.7 diversified
451 E. Kroenke U.S. 1.7 sports, real estate
451 Joseph Lau Hong Kong 1.7 real estate
451 Mary Alice Dorrance Malone U.S. 1.7 inheritance
451 Gregorio Perez Companc & family Argentina 1.7 oil & gas
451 Anthony Pritzker U.S. 1.7 hotels, investments
451 Daniel Pritzker U.S. 1.7 hotels, investments
451 James Pritzker U.S. 1.7 hotels, investments
451 Jay Robert (JB) Pritzker U.S. 1.7 hotels, investments
451 Jean (Gigi) Pritzker U.S. 1.7 hotels, investments
451 John Pritzker U.S. 1.7 hotels, investments
451 Karen Pritzker U.S. 1.7 hotels, investments
451 Linda Pritzker U.S. 1.7 hotels, investments
451 Larry Rong Zhijian China 1.7 diversified
451 Omer Sabanci Turkey 1.7 diversified
451 Sevket Sabanci Turkey 1.7 diversified
451 Walter Scott Jr. U.S. 1.7 construction,
telecom
451 Sylvia Stroeher Germany 1.7 cosmetics
451 Lucio Tan Philippines 1.7 diversified
451 Wong Kwong Yu China 1.7 appliances
451 Igor Zyuzin Russia 1.7 mining, steel
486 Julio Bozano Brazil 1.6 banking
486 Jim Davis & family U.S. 1.6 New Balance
486 Abilio dos Santos Diniz Brazil 1.6 supermarkets
486 Aydin Dogan Turkey 1.6 media
486 Ray Dolby U.S. 1.6 Dolby Laboratories
486 Donald Gordon South Africa 1.6 insurance, malls
486 Jon Huntsman U.S. 1.6 chemicals
486 Ryoichi Jinnai Japan 1.6 credit
486 Min Kao U.S. 1.6 navigation equipment
486 Daryl Katz Canada 1.6 pharmacies
486 Barry Lam Taiwan 1.6 laptops
486 Lee Shin Cheng Malaysia 1.6 agriculture
486 Joseph Lewis U.K. 1.6 finance
486 John Malone U.S. 1.6 cable television
486 John Marriott Jr. U.S. 1.6 hotels
486 E. Marshall U.S. 1.6 investments
486 Alain Merieux & family France 1.6 biotech
486 William Pulte U.S. 1.6 home building
486 Dmitry Rybolovlev Russia 1.6 fertilizer
486 David Sainsbury U.K. 1.6 supermarkets
486 Eduard Shifrin U.K. 1.6 steel
486 Alexander Shnaider Canada 1.6 steel
486 Thomas Siebel U.S. 1.6 Siebel Systems
486 Patrick Soon-Shiong U.S. 1.6 generic drugs
486 Arne Wilhelmsen & family Norway 1.6 tankers, cruise
ships
486 Elizabeth Wiskemann U.S. 1.6 mutual funds
512 Peter Buck U.S. 1.5 Subway
512 John Caudwell U.K. 1.5 mobile phones
512 Turgay Ciner Turkey 1.5 diversified
512 Hasan Colakoglu Turkey 1.5 diversified
512 Jean Coutu Canada 1.5 pharmacies
512 Fred DeLuca U.S. 1.5 Subway
512 Archie Aldis (Red) Emmerson U.S. 1.5 timberland,
lumber mills
512 Gerald Ford U.S. 1.5 banking
512 James France U.S. 1.5 auto racing
512 William France Jr. U.S. 1.5 auto racing
512 Victor Fung U.S. 1.5 distribution
512 William Fung Hong Kong 1.5 apparel
512 Rolf Gerling Germany 1.5 insurance
512 Naresh Goyal India 1.5 aviation
512 Kenneth Griffin U.S. 1.5 hedge funds
512 Marguerite Harbert U.S. 1.5 inheritance
512 Kenneth Hendricks U.S. 1.5 building supplies
512 Thomas Hunter U.K. 1.5 investments
512 Stephen Jarislowsky Canada 1.5 asset management
512 H Fisk Johnson U.S. 1.5 SC Johnson & Sons
512 Imogene Powers Johnson U.S. 1.5 SC Johnson & Sons
512 Helen Johnson-Leipold U.S. 1.5 SC Johnson & Sons
512 Winnie Johnson-Marquart U.S. 1.5 SC Johnson & Sons
512 James Kim & family U.S. 1.5 microchips
512 Alicia Koplowitz Spain 1.5 investments
512 Michael Krasny U.S. 1.5 CDW Corp.
512 Tracy Krohn U.S. 1.5 W&T Offshore
512 George Lindemann & family U.S. 1.5 investments
512 Lui Che Woo Hong Kong 1.5 construction, gaming
512 Richard Marriott U.S. 1.5 hotels
512 Charles Munger U.S. 1.5 Berkshire Hathaway
512 Husnu Ozyegin Turkey 1.5 banking
512 Liselott Persson Sweden 1.5 Hennes & Mauritz
512 T. Boone Pickens U.S. 1.5 oil & gas,
investments
512 Stewart Rahr U.S. 1.5 Kinray
512 Marc Rich U.S. 1.5 commodities
512 Ferit Sahenk Turkey 1.5 diversified
512 Bernard Saul II U.S. 1.5 banking, real estate
512 Kavitark Shriram U.S. 1.5 Google
512 John Sperling U.S. 1.5 Apollo Group
512 Pat Stryker U.S. 1.5 Stryker Corp.
512 Henry Sy & family Philippines 1.5 malls
512 Marcel Herman Telles Brazil 1.5 beer
512 Andreas von Bechtolsheim Germany 1.5 Google
512 Margaret Whitman U.S. 1.5 EBay
512 John Whittaker U.K. 1.5 real estate
512 Arthur Williams Jr. U.S. 1.5 insurance
512 Daniel Ziff U.S. 1.5 inheritance,
hedge funds
512 Dirk Ziff U.S. 1.5 inheritance,
hedge funds
512 Robert Ziff U.S. 1.5 inheritance,
hedge funds
562 Abdulla Al Futtaim United Arab 1.4 auto dealers,
Emirates investments
562 Bassam Alghanim Kuwait 1.4 finance
562 Kutayba Alghanim Kuwait 1.4 diversified
562 John Anderson U.S. 1.4 investments
562 George Argyros U.S. 1.4 investments
562 Sid Bass U.S. 1.4 oil, investments
562 Frank Batten Sr. U.S. 1.4 Landmark
562 Neil Bluhm U.S. 1.4 real estate
562 William Boyd U.S. 1.4 casinos, banking
562 Robert Day U.S. 1.4 money management
562 Edward Debartolo Jr. U.S. 1.4 shopping centers
562 N. Murray Edwards Canada 1.4 oil & gas
562 Barbara Carlson Gage & family U.S. 1.4 Carlson Cos.
562 John Gandel Australia 1.4 real estate
562 Leslie Gonda U.S. 1.4 International
Lease Finance
562 Hind Hariri Lebanon 1.4 inheritance
562 Jonathan Harmsworth U.K. 1.4 publishing
562 Alfredo Harp Helu Mexico 1.4 banking
562 Richard Hayne U.S. 1.4 Urban Outfitters
562 Ming Hsieh U.S. 1.4 Cogent Systems
562 Joseph Jamail Jr. U.S. 1.4 lawsuits
562 Baba Kalyani India 1.4 engineering
562 Guy Laliberte Canada 1.4 Cirque du Soleil
562 Guilherme Peirao Leal Brazil 1.4 cosmetics
562 Myung-Hee Lee South Korea 1.4 retail
562 Nancy Lerner U.S. 1.4 inheritance
562 Norma Lerner U.S. 1.4 inheritance
562 Randolph Lerner U.S. 1.4 inheritance
562 Vincent Lo Hong Kong 1.4 real estate
562 Robert McNair U.S. 1.4 energy, sports
562 James Moran U.S. 1.4 auto dealerships
562 Marilyn Carlson Nelson & family U.S. 1.4 Carlson Cos.
562 Anthony O'Reilly Ireland 1.4 publishing
562 Michael Price U.S. 1.4 investments
562 Hans Riegel Germany 1.4 candy
562 Paul Riegel Germany 1.4 candy
562 Isaac Saba Raffoul & family Mexico 1.4 diversified
562 Antonio Luiz Seabra Brazil 1.4 cosmetics
562 Ollen Smith U.S. 1.4 Speedway Motorsports
562 Peter Sperling U.S. 1.4 Apollo Group
562 Tulsi Tanti India 1.4 wind energy
562 Albert Ueltschi U.S. 1.4 FlightSafety
562 Sanford Weill U.S. 1.4 Citigroup
562 Oprah Winfrey U.S. 1.4 television
606 Vasiliy Anisimov Russia 1.3 metals, real estate
606 Semahat Arsel Turkey 1.3 diversified
606 Arthur Blank U.S. 1.3 Home Depot
606 Barry Diller U.S. 1.3 InterActiveCorp
606 Lloyd Dorfman U.K. 1.3 Travelex
606 Richard Egan U.S. 1.3 EMC Corp.
606 Richard Farmer U.S. 1.3 Cintas Corp.
606 John J. Fisher U.S. 1.3 Gap
606 Robert Fisher U.S. 1.3 Gap
606 William Fisher U.S. 1.3 Gap
606 Thomas Flatley U.S. 1.3 real estate
606 Alan Gerry U.S. 1.3 cable television
606 Malcolm Glazer U.S. 1.3 investments
606 Christopher Goldsbury U.S. 1.3 salsa
606 Blase Golisano U.S. 1.3 Paychex
606 Alec Gores U.S. 1.3 leveraged buyouts
606 Robert Holding U.S. 1.3 energy, resorts,
ranching
606 Elie Horn Brazil 1.3 real estate
606 Donald Horton U.S. 1.3 DR Horton
606 James Jannard U.S. 1.3 Oakley
606 Brad Kelley U.S. 1.3 tobacco
606 Thomas Lee U.S. 1.3 leveraged buyouts
606 James Leprino U.S. 1.3 cheese
606 Liu Yongxing China 1.3 agriculture,
aluminum
606 Gary Michelson U.S. 1.3 medical patents
606 John Morgridge U.S. 1.3 Cisco
606 Hideo Morita & family Japan 1.3 Sony
606 Nicholas Pritzker II U.S. 1.3 hotels, investments
606 James Ratcliffe U.K. 1.3 Ineos
606 Phillip Ruffin U.S. 1.3 casinos, real estate
606 Erol Sabanci Turkey 1.3 diversified
606 Filiz Sahenk Turkey 1.3 diversified
606 Carlos Alberto Sicupira Brazil 1.3 beer
606 Alexander Spanos U.S. 1.3 real estate
606 Harry Triguboff Australia 1.3 real estate
606 Joop van den Ende Netherlands 1.3 TV
606 Martin Viessmann Germany 1.3 heating equipment
606 Dean White U.S. 1.3 billboards, hotels
606 Jaime Zobel de Ayala & family Philippines 1.3 diversified
645 Thomas Bailey U.S. 1.2 mutual funds
645 Edward Bass U.S. 1.2 oil, investments
645 Carl Berg U.S. 1.2 real estate
645 Timothy Blixseth U.S. 1.2 timber, real estate
645 Amar Bose U.S. 1.2 Bose
645 Alan Casden U.S. 1.2 real estate
645 Harvey Chaplin & family U.S. 1.2 liquor, wine
distribution
645 William Connor II U.S. 1.2 exports
645 Scott Cook U.S. 1.2 Intuit
645 David Copley U.S. 1.2 newspapers
645 William Ding China 1.2 internet
645 Roy Disney U.S. 1.2 Walt Disney
645 J. Flowers U.S. 1.2 investments
645 Robert Friedland U.S. 1.2 mining
645 Dr. Phillip Frost U.S. 1.2 Ivax
645 Soichiro Fukutake Japan 1.2 education
645 Ernest Gallo U.S. 1.2 wine
645 Pincus Green U.S. 1.2 commodities
645 Ingeburg Herz Germany 1.2 coffee
645 Stanley Stub Hubbard U.S. 1.2 DirecTV
645 Pauline MacMillan Keinath U.S. 1.2 inheritance
645 Suna Kirac Turkey 1.2 diversified
645 Jerome Kohlberg Jr. U.S. 1.2 leveraged buyouts
645 Cargill MacMillan Jr. U.S. 1.2 inheritance
645 John MacMillan III U.S. 1.2 inheritance
645 W MacMillan U.S. 1.2 inheritance
645 Whitney MacMillan U.S. 1.2 inheritance
645 Billy Joe (Red) McCombs U.S. 1.2 radio, oil, real
estate
645 Robert McLane Jr. U.S. 1.2 Wal-Mart, logistics
645 William Morean U.S. 1.2 Jabil Circuit
645 Arturo Moreno U.S. 1.2 billboards
645 N.R. Narayana Murthy India 1.2 software
645 Kazuo Okada & family Japan 1.2 gaming
645 Kenshin Oshima Japan 1.2 finance
645 Tuncay Ozilhan Turkey 1.2 beverages
645 Jorge Perez U.S. 1.2 home building
645 Marion MacMillan Pictet U.S. 1.2 inheritance
645 Victor Pinchuk Ukraine 1.2 steel pipes
645 Winthrop Rockefeller U.S. 1.2 Standard Oil,
banking
645 Steven Roth U.S. 1.2 real estate
645 Herbert Sandler U.S. 1.2 banking
645 Richard Scaife U.S. 1.2 inheritance
645 Donald Schneider U.S. 1.2 trucking
645 Dorothea Steinbruch & family Brazil 1.2 steel
645 Serhiy Taruta Ukraine 1.2 steel, coal
645 A. Alfred Taubman U.S. 1.2 real estate
645 Phyllis Taylor U.S. 1.2 Taylor Energy
645 David Tepper U.S. 1.2 hedge funds
645 Wilma Tisch & family U.S. 1.2 Loews
645 Yoshiaki Tsutsumi Japan 1.2 real estate
645 Peter Unger Germany 1.2 auto repair
645 Theodore Waitt U.S. 1.2 Gateway
645 Tadahiro Yoshida & family Japan 1.2 zippers
698 Edmund Ansin U.S. 1.1 Sunbeam Broadcasting
698 John Arrillaga U.S. 1.1 real estate
698 Anneliese Brost Germany 1.1 newspapers
698 Gary Burrell U.S. 1.1 navigation equipment
698 James Cayne U.S. 1.1 Bear Stearns
698 Chu Mang Yee China 1.1 real estate
698 Henrique Constantino Brazil 1.1 GOL airlines
698 Joaquim Constantino Neto Brazil 1.1 GOL airlines
698 Ricardo Constantino Brazil 1.1 GOL airlines
698 Constantino de Oliveira Jr. Brazil 1.1 GOL airlines
698 David Duffield U.S. 1.1 PeopleSoft
698 Bulent Eczacibasi Turkey 1.1 pharmaceuticals
698 Paul Fireman U.S. 1.1 Reebok
698 Kenneth Fisher U.S. 1.1 money management
698 William Ford Sr. U.S. 1.1 Ford Motor Co.
698 Mario Gabelli U.S. 1.1 money management
698 Robert Galvin U.S. 1.1 Motorola
698 David Gottesman U.S. 1.1 investments
698 William Gross U.S. 1.1 bonds
698 Guo Guangchang China 1.1 diversified
698 Albert Gubay U.K. 1.1 real estate
698 Han Chang-Woo & family Japan 1.1 gaming
698 Dietmar Hopp Germany 1.1 SAP
698 Hui Wing Mau China 1.1 real estate
698 Jerral Jones U.S. 1.1 Dallas Cowboys
698 George Joseph U.S. 1.1 insurance
698 Katsuhiro Kinoshita Japan 1.1 credit
698 Kyosuke Kinoshita Japan 1.1 credit
698 Shigeyoshi Kinoshita Japan 1.1 credit
698 Uday Kotak India 1.1 banking
698 Robert Kraft U.S. 1.1 paper, packaging
698 Kenneth Langone U.S. 1.1 investments
698 Richard Li Hong Kong 1.1 telecom
698 Robert Naify U.S. 1.1 movie theaters
698 Richard Peery U.S. 1.1 real estate
698 Nelson Peltz U.S. 1.1 leveraged buyouts
698 Jesse Robinson U.S. 1.1 banking, insurance
698 Edward Roski Jr. U.S. 1.1 real estate
698 Marion Sandler U.S. 1.1 banking
698 Hajime Satomi Japan 1.1 gaming
698 Herbert Siegel U.S. 1.1 television
698 Herbert Simon U.S. 1.1 real estate
698 Joyce Raley Teel U.S. 1.1 supermarkets
698 Kenny Troutt U.S. 1.1 Excel Communications
698 Charlotte Colket Weber U.S. 1.1 inheritance
698 Kamil Yazici Turkey 1.1 beverages
698 Yeoh Tiong Lay & family Malaysia 1.1 construction
698 Ahmet Zorlu Turkey 1.1 electronics, finance
746 Majid Al Futtaim United Arab 1.0 real estate
Emirates
746 Mahdi Al-Tajir United Arab 1.0 investments
Emirates
746 Calvin Ayre Canada 1.0 Bodog.com
746 Louis Bacon U.S. 1.0 hedge funds
746 Perry Bass U.S. 1.0 oil, investments
746 Subhash Chandra India 1.0 media
746 David Cheriton Canada 1.0 Google
746 Gary Comer U.S. 1.0 Lands' End
746 Leszek Czarnecki Poland 1.0 leasing, banking
746 Dermot Desmond Ireland 1.0 finance
746 Richard Desmond U.K. 1.0 publishing
746 Omer Dinckok Turkey 1.0 diversified
746 L. Doerr U.S. 1.0 venture capital
746 James Dyson U.K. 1.0 technology
746 John Edson U.S. 1.0 leisure craft
746 Marvin Herb U.S. 1.0 soft-drink bottling
746 William Hilton U.S. 1.0 hotels, casinos
746 Jeremy Jacobs Sr. U.S. 1.0 sports concessions
746 Michael Jaharis U.S. 1.0 pharmaceuticals
746 Morris Kahn Israel 1.0 software
746 Mehmet Karamehmet & family Turkey 1.0 finance, telecom
746 William Kellogg U.S. 1.0 Kohl's
746 Nasser Khalili U.K. 1.0 art, real estate
746 Habil Khorakiwala India 1.0 pharmaceuticals
746 Asim Kibar Turkey 1.0 diversified
746 Jan Kulczyk Poland 1.0 telecom, oil, beer
746 Liu Yonghao China 1.0 agriculture,
investments
746 Vijay Mallya India 1.0 liquor
746 Anne Windfohr Marion U.S. 1.0 inheritance, oil
746 Bernard Osher U.S. 1.0 banking, investments
746 Wilbur Ross Jr. U.S. 1.0 leveraged buyouts
746 Joanne (J.K.) Rowling U.K. 1.0 Harry Potter
746 Lily Safra Monaco 1.0 inheritance
746 Silvio Scaglia Italy 1.0 telecom
746 Monika Schoeller Germany 1.0 publishing
746 Charles Simonyi U.S. 1.0 Microsoft
746 Sheldon Solow U.S. 1.0 9 West 57th
746 John Stanton U.S. 1.0 wireless
746 Kerry Stokes Australia 1.0 media, Caterpillar
746 Tiong Hiew King Malaysia 1.0 timber
746 Hope Hill Van Beuren U.S. 1.0 inheritance
746 Murat Vargi Turkey 1.0 telecom
746 Dieter von Holtzbrinck Germany 1.0 publishing
746 Stefan von Holtzbrinck Germany 1.0 publishing
746 Todd Wagner U.S. 1.0 Broadcast.com
746 Samuel Wyly U.S. 1.0 investments
746 Faruk Yalcin Turkey 1.0 manufacturing
746 Jerry Zucker U.S. 1.0 industrialist

To contact the reporter on this story: Heather Burke in New York at [e-mail] .
Last Updated: March 9, 2006 18:00 EST

[BikiniAnalyst]

http://southflorida.bizjournals.com/southflorida/stories/200…


Frost buys another biotech
South Florida Business Journal - May 16, 2007
by Brian Bandell

Miami billionaire Dr. Phillip Frost and his investment team have done it again, purchasing a large stake in another publicly traded biotech company through a merger.

A company official said the new company may consider moving to Miami, which would put it near several other companies in which Frost has recently invested.

In the most recent deal, which closed Tuesday, Vienna, Va.-based Modigene closed a $9.6 million private placement, merging with Modigene Delaware. Frost and Dr. Jane Hsiao, who worked with Frost at Miami-based Ivax Corp. until Frost sold the company, joined the company's board of directors.

Frost and Hsiao, plus two other former Ivax executives, made a $2 million private placement in Modigene. In exchange, they received 5.4 million shares of common stock and warrants to purchase 333,333 more shares or enough to maintain at least a 15 percent stake in the company.

Investors in the $9.6 million private placement received 6.4 million shares at $1.50 each and warrants to purchase 1.6 million more shares at $2.50 each.

"We are excited about the Modigene opportunity and believe in the management team, products, and underlying technology," Frost said. "We look forward to working together with the board of directors and management in building Modigene into a significant player in the therapeutic proteins market."

Modigene's technology is based on a short amino acid sequence called carboxyl terminal peptide discovered at Washington University in St. Louis. The sequence is being testing to see if it can treat multiple sclerosis, anemia and growth failure in children and adults.

Since selling Ivax to Israel-based Teva Pharmaceutical for $7.4 billion at the beginning of last year, Frost has been busy acquiring interests in companies and has moved many of them to Miami. For example, he moved investment bank Ladenburg Thalmann & Co. from New York and Opko Corp. from Philadelphia after getting a controlling interest.

"We will consider this option, as well, although nothing has been decided yet," Modigene President Shai Novik said.

[BikiniAnalyst]

http://www.fiercebiotech.com/story/frost-makes-another-deal-…

Frost makes another deal for biotech company
May 17, 2007

Billionaire biotech investor Dr. Phillip Frost has inked another deal - the latest in a series of transactions involving small, private drug developers. Frost picked up a significant interest in Modigene, a biotech company that focuses on a short amino acid sequence that may play a role in treating multiple sclerosis, anemia and growth failure. Dr. Frost and Dr. Jane Hsiao, a colleague of Dr. Frost's at Ivax before Frost sold the company in a multibillion-dollar deal, and two other former Ivax executives made a $2 million private placement in Modigene. They'll receive stock and warrants that would give them at least a 15 percent stake in the company. That money was part of an $11.6 million private placement by Modigene, which involved a merger with Modigene Inc., a Delaware company. Just days ago Frost completed a deal that merged Acuity Pharmaceuticals and Froptix into the publicly traded Opko Corp., based in Miami.

"We are excited about the Modigene opportunity and believe in the management team, products, and underlying technology," Frost said. "We look forward to working together with the board of directors and management in building Modigene into a significant player in the therapeutic proteins market."

[Zocker_Freak]

Interessante Aktie! Werd ich mir mal die nächsten Tage ansehen.

Vor allem das Management gefällt mir gut, die haben schon andere Firmen nach oben gebracht

[BikiniAnalyst]

hier mal Realtime usa-kurs

[BikiniAnalyst]

Antwort auf Beitrag Nr.: 30.018.444 von Zocker_Freak am 19.06.07 14:21:01

Richtig erkannt!

Die haben da schon ein feines Mngmt-Team zusammengestellt

[Zocker_Freak]

Hier die Widerstände und Unterstützungen im US-Chart:

Support/Resistance
Type Value Conf.
resist. 3.01 1
resist. 2.82 2
resist. 2.34 2
resist. 2.21 4 <---- 1 Cent über gestrigen Schlusskurs
supp 1.99 4
supp 1.74 3
supp 1.41 3
supp 1.09 4

http://www.stockta.com/cgi-bin/analysis.pl?symb=MODG&num1=3&…

Analysis
Overall Short Intermediate Long
Bullish (0.37) Bullish (0.38) Neutral (0.23) Very Bullish (0.50)

[klugerschachzug]

Äußerst informativer Thread.

Hab mir mal ein paar Stücke von MODIGENE gekauft.

Rechne hier mit einer konservativen positiven Entwicklung.

Pro Jahr 100% reicht mir schon

[klugerschachzug]

Hier ist ein Board aus USA, dort spricht man auch über MODG wie ich grad gesehen hab.

http://www.marketmillionaires.com/small-cap-stocks-1-00-10-0…

[klugerschachzug]

Anyone check this out yet? Nice bounce off of $2 area seems so far strong support at that level. This Dr. Frost has a great track record where he has invested his own $$ outright and gotten involved in the companies; this looks like another of the same.



http://www.marketmillionaires.com/115001-post3.html

[BikiniAnalyst]

Über den Widerstand von 2,21 USD wären wir jetzt.

Stehen aktuell bei 2,25 US$


Hier der RT-Chart von MODG in USA

[BikiniAnalyst]

Antwort auf Beitrag Nr.: 30.072.531 von klugerschachzug am 20.06.07 13:20:37

Danke für dein Lob, und herzlich willkommen in der Runde.

100% p.a. da bist du bei MODG ganz gut aufgehoben fürs Erste!

[tsylver]

Press Release Source: Modigene Inc.


Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
Wednesday June 20, 9:00 am ET


VIENNA, Va., June 20 /PRNewswire/ -- Modigene Inc., a Nevada corporation (OTC Bulletin Board: MODG - News) today announced the successful completion of pharmacokinetic and pharmacodynamic pre-clinical experiments for long-acting human growth hormone, long-acting interferon beta and long-acting erythropoietin.

Modigene's pharmacodynamic and pharmacokinetic pre-clinical experiments demonstrated superb durability of the long-acting proteins, indicating a potential administration protocol in patients of once per week or up to once every four weeks, pending the specific protein and disease indication. The models were conducted using the industry standard animal models and methods as well as comparative studies to the commercially available versions. Human growth hormone is used to treat growth failure in children and adults, is injected 3-7 times per week, and has an existing estimated market size of $2.2 billion; while interferon beta is prescribed for the treatment of multiple sclerosis, is injected 1-3 times per week, and has an existing estimated market size of $3.8 billion. Neither of these markets currently have a commercial long-acting version available.

In addition, Modigene's long-acting erythropoietin has demonstrated, in a pre-clinical animal model comparative study, increased durability and biological effect over Amgen Inc.'s Aranesp®, a long-acting erythropoietin with reported sales of $4.1 billion in 2006, out of a total estimated EPO market size of $11.7 billion. Erythropoietin is prescribed for the treatment of anemia.

"We are very excited about Modigene's pre-clinical work to date," said Dr. Phillip Frost, Vice Chairman of Teva Pharmaceutical Industries, and Modigene's largest shareholder and board member. "With four CTP-modified proteins demonstrating to date exceptional results, including Schering-Plough/Organon's FSH-CTP now in Phase III clinical trial, and Modigene's human growth hormone, interferon beta and EPO in pre-clinical models, the CTP platform is gaining credibility as having the potential to become the platform of choice for developing long-acting therapeutic proteins."

"The accomplishment of this milestone was important for Modigene as it continues its long-acting protein programs, and as a key indicator that the CTP platform is universal and could be applicable to a variety of therapeutic proteins and peptides that suffer from weak durability and hence dictate short injection frequencies," said Shai Novik, Modigene's President. "We are moving forward with our preparations for GMP production of our lead protein candidates and initiation of clinical trials thereafter. We have also commenced development of a long-acting version of GLP-1, a therapeutic peptide that is prescribed for diabetes type II patients, and is currently injected twice daily, and will continue to apply the technology to several other key blockbuster therapeutic proteins."

Modigene's technology was discovered by researchers at Washington University in St. Louis, Missouri, and is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in the human body, and when attached to a therapeutic protein, extends the time that such protein can last effectively in the body. This has been demonstrated and validated by Organon -- which, on March 12 2007, announced a deal to be acquired by Schering-Plough for $14.4 billion. Organon also licenses the CTP technology from Washington University, and has attached the CTP to a Follicle- Stimulating Hormone (FSH) -- a hormone with approximately $1 billion in annual sales that is prescribed for females undergoing fertility treatments. Organon is currently in Phase III clinical trials with its FSH-CTP product, which could complete during 2007. Phase II trials demonstrated that a single injection of FSH-CTP was able to provide the same clinical effect as 7 consecutive daily injections of commercial FSH. These trials demonstrated that attaching the CTP did not affect the therapeutic activity of FSH or cause a negative immune system response in patients. Modigene has an exclusive license with Washington University for use of the CTP with all proteins except four endocrine proteins, which are licensed to Schering-Plough/Organon.

ABOUT MODIGENE

Modigene Inc. (OTCBB: MODG - News) is a publicly-traded biopharmaceutical company utilizing patented technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions in annual global sales. Modigene is currently developing long-acting versions of human growth hormone, erythropoietin, interferon beta, and GLP-1 -- each representing a multi-billion dollar market. For more information on Modigene, please visit www.modigeneinc.com.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding the results of current studies and pre-clinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.


Source: Modigene Inc.

[BikiniAnalyst]

Antwort auf Beitrag Nr.: 30.076.784 von tsylver am 20.06.07 16:44:33

cool, ne news gabs heute auch!

hier die quelle: http://modigeneinc.com/News%5CNewshGHIFNEPOJune2007.pdf

Modigene Announces Successful Completion of Pharmacokinetic &
Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting
Human Growth Hormone, Long-acting Interferon Beta and Long-acting
Erythropoietin

[tsylver]

Antwort auf Beitrag Nr.: 30.076.784 von tsylver am 20.06.07 16:44:33

wie schätzt Ihr diese Nachricht ein? hört sich doch nicht schlecht an, oder?
die Frage ist, welchen Anteil an dem "billion $"-Markt sich Modigene sichert?

[BikiniAnalyst]

Die letzen Umsätze von MODG an der OTCBB von gestern. Schluss war auf 2.30 $

Seit Threaderöffnung sind wir jetzt schon von 2.20$ auf 2.30$ bzw. von 1,64 € auf 1,71 € gestiegen


Price Size Exch Time
2.30 500 OBB 06/20
2.30 1600 OBB 06/20
2.30 500 OBB 06/20
2.30 2200 OBB 06/20
2.30 2200 OBB 06/20
2.29 1000 OBB 06/20
2.29 1000 OBB 06/20
2.30 5000 OBB 06/20
2.28 2500 OBB 06/20
2.25 500 OBB 06/20
2.25 500 OBB 06/20
2.25 1000 OBB 06/20
2.25 1000 OBB 06/20
2.25 1000 OBB 06/20
2.25 10000 OBB 06/20
2.25 3000 OBB 06/20
2.25 3000 OBB 06/20
2.25 500 OBB 06/20
2.25 2000 OBB 06/20
2.25 2500 OBB 06/20
2.25 2500 OBB 06/20
2.25 500 OBB 06/20
2.25 5000 OBB 06/20
2.25 500 OBB 06/20
2.25 1000 OBB 06/20
2.25 500 OBB 06/20
2.25 500 OBB 06/20
2.22 1500 OBB 06/20
2.22 200 OBB 06/20
2.24 500 OBB 06/20

[BikiniAnalyst]

Antwort auf Beitrag Nr.: 30.084.880 von tsylver am 20.06.07 23:55:54

Also ich finde die News äußerst positiv. Sollte sich die nächsten Tage und Wochen noch auswirken.

Vorklinische Studien erfolgreich abgeschlossen

\"We are very excited about Modigene\'s pre-clinical work to date,\" said Dr. Phillip Frost, Vice Chairman of Teva Pharmaceutical Industries, and Modigene\'s largest shareholder and board member. \"With four CTP-modified proteins demonstrating to date exceptional results, including Schering-Plough/Organon\'s FSH-CTP now in Phase III clinical trial, and Modigene\'s human growth hormone, interferon beta and EPO in pre-clinical models, the CTP platform is gaining credibility as having the potential to become the platform of choice for developing long-acting therapeutic proteins.\"

\"The accomplishment of this milestone was important for Modigene as it continues its long-acting protein programs, and as a key indicator that the CTP platform is universal and could be applicable to a variety of therapeutic proteins and peptides that suffer from weak durability and hence dictate short injection frequencies,\" said Shai Novik, Modigene\'s President. \"We are moving forward with our preparations for GMP production of our lead protein candidates and initiation of clinical trials thereafter. We have also commenced development of a long-acting version of GLP-1, a therapeutic peptide that is prescribed for diabetes type II patients, and is currently injected twice daily, and will continue to apply the technology to several other key blockbuster therapeutic proteins.\"

[BikiniAnalyst]

[BikiniAnalyst]

Modigene is currently developing long-lasting versions for the following existing therapeutic proteins:

* MOD-401: hGH-CTP – $2.2 billion current market, no available long-lasting therapeutic


* MOD-701: EPO-CTP - $10.7 billion current market, available long-lasting therapeutics


* MOD-901: IFN-ß-CTP – $3.8 billion current market, no available long-lasting therapeutic


* MOD-1001: GLP-1-CTP – $1.0 billion estimated potential market, no available long-lasting therapeutics

[BikiniAnalyst]

The Modigene R&D facility includes the following laboratories:

* Molecular biology


* Cell culture


* In-vitro (laboratory) potency and activity testing


* Protein purification


These laboratories continuously support the development and the supply of the required quantities of purified proteins in order to assess the proof-of-concept of each modified protein utilizing in-vitro as well as in-vivo animal models. Following the proof-of concept stage for each drug candidate, Modigene outsources its production to certified subcontractors in order to prepare the required material for clinical trial phases. One of the main advantages of Modigene's CTP technology is that the long-lasting proteins are produced by standard cell lines used by most leading biotech companies, and as such there are high quality certified subcontractors that are providing production services to these leading biotech companies, and to Modigene as well. This eliminates the need for Modigene to spend significant capital investments on proprietary production facilities.

Modigene’s facility is located in Weizmann Science Park in Nes Ziona – the leading biotech cluster in Israel and the base of over 60 biotech companies including top certified service providers in analytical development, process development, pharmaceutical development and pre-clinical services.

[BikiniAnalyst]

Also lt. Zocker_Freak nächster (schwacher) Widerstand im Chart bei 2,34$ da sind wir seit gestern nur noch 4 cents entfernt

Support/ Resistance
Type Value Conf.
resist. 3.01 1
resist. 2.82 2
resist. 2.34 2 holen wir uns als nächstes
resist. 2.21 4 (wurde gestern übersprungen)
supp 1.99 4
supp 1.74 3
supp 1.41 3
supp 1.09 4

[Zocker_Freak]

Toller Wert, schön langsam nach oben. Substanz das zählt! Und die ist hier vorhanden

[klugerschachzug]

Hallo miteinander!

Ziemlich ruhig heute...

"Die Ruhe vor dem Sturm?"

[klugerschachzug]

Was ich mir mal überlegt hab: Dieser Dr. Frost, der ja bei Modigene eingestiegen ist...

Ich meine der Typ ist Milliardär, gehört zu den reichsten Menschen dieses Planeten und hat schon andere Biotech-Firmen nach oben gebracht. Entweder wurden diese übernommen für einen weitaus höheren Preis, oder aber sie entwickelten sich schnurstracks nach oben. Ausgezeichneter Track-Record eben!

Außerdem hat er viele Kollegen seiner "Ex-Firme" mit zu Modigene gebracht.

Er ist im Aufsichtsrat von Modi, und wird schon wissen in was und vor allem warum er da investiert. Dies alles sind Gründe für mich gewesen hier einzusteigen. Im moment 1,70 € in Frankfurt. Ende nächsten Monat sollten wir locker über 2 € sein

[tsylver]

anbei ein Bericht über die Erfolgsmeldung vom 20.06.:

http://www.in-pharmatechnologist.com/news/ng.asp?n=77533-mod…

[Zocker_Freak]

Antwort auf Beitrag Nr.: 30.105.254 von tsylver am 22.06.07 00:10:56

cool!

Hier mit Link:



http://www.in-pharmatechnologist.com/news/ng.asp?n=77533-mod…

[Zocker_Freak]

Technology for long-acting proteins here to stay

By Katrina Megget

20/06/2007 - Modigene has made inroads into its development of long-acting proteins through the use of its Carboxyl Terminal Peptide (CTP) technology.

The Virginia-based biopharmaceutical company announced positive results for its long-lasting pre-clinical formulations of human growth hormone, interferon beta and erythropoietin, which aim to be, at most, once per week injections.

This would be a stark therapeutic contrast to the three-plus a week injections required with the currently marketed drugs.

Over the past few years there has been a real drive by biopharm companies to extend the life span of therapeutic proteins, with two main techniques evolving. One is to increase the size of the therapeutic protein; the other is to alter the physical structure.

However, there are downfalls with these techniques and as a result only three long-lasting therapeutic proteins are on the market: Pegasys (PEGinterferon alfa-2A) from Schering-Plough and Roche for the treatment of hepatitis C; Aranesp (Darbepoetin alfa) from Amgen for the treatment of anemia; and Neulasta (PEGfilgrastim) from Amgen a colony stimulating factor.

Collectively, these treatments have a revenue of more than $8bn a year.

Modigene's technology however, takes a mother nature approach to finding a long-lasting solution.

Discovered by researchers at Washington University in St. Louis, Missouri, CTP technology involves using CTP, a small peptide naturally occurring in the body as a portion of the protein human Chorionic Gonadotropin (hCG), a female hormone that helps maintain pregnancy.

By attaching CTP to other proteins it can extend the life span of the protein. Meanwhile, as both females and males, during the nine-month pregnancy period, are exposed to the protein, there is less likelihood of having an immune response to it.

Currently, Dutch biotech company Organon has attached CTP to a follicle-stimulating hormone (FSH), which is a hormone prescribed to females undergoing fertility treatments, and is in Phase III clinical trials with the product. So far, results suggest only one injection is required with FSH-CTP compared to the seven daily injections required with regular FSH.

"We are very excited about Modigene's pre-clinical work to date," Modigene's largest shareholder and board member and Teva Pharmaceutical Industries vice chairman Dr Phillip Frost said in a statement.

"With four CTP-modified proteins demonstrating to date exceptional results, including Schering-Plough/Organon's FSH-CTP now in Phase III clinical trial, and Modigene's human growth hormone, interferon beta and EPO [erythropoietin] in pre-clinical models, the CTP platform is gaining credibility as having the potential to become the platform of choice for developing long-acting therapeutic proteins."

The advantages with the technology show CTP can be attached to a variety of proteins without increasing toxicity or loss of biological activity.

According to Modigene's website, CTP-modified proteins can be manufactured using established recombinant DNA techniques in widely used mammalian protein expression systems.

"The accomplishment of this milestone was important for Modigene," the company's president Shai Novik said in a statement.

"We are moving forward with our preparations for GMP production of our lead protein candidates and initiation of clinical trials thereafter. We have also commenced development of a long-acting version of GLP-1, a therapeutic peptide that is prescribed for diabetes type II patients, and is currently injected twice daily, and will continue to apply the technology to several other key blockbuster therapeutic proteins," he said.

The three proteins Modigene are developing reflect a big-bucks segment in the pharmaceutical industry. The human growth hormone market is worth about $2.2bn; interferon, prescribed for the treatment of multiple sclerosis, is worth $3.8bn; and Amgen's Aranesp reported sales of $4.1bn last year, out of estimated EPO market of $11.7bn.

Just yesterday, Merck-Serono announced it would be collaborating with US firm Ambrx on the development and commercialization of new product ARX201, a long-acting growth hormone product, using Ambrx's protein engineering platform ReCODE. The technology enhances hGH performance by allowing precise positioning of the site of a polyethylene glycol (PEG) polymer through biosynthetically incorporating a chemically unique amino acid.

[klugerschachzug]

Antwort auf Beitrag Nr.: 30.141.207 von Zocker_Freak am 22.06.07 09:08:49

Alles in allem würde ich sagen TOP NEWS.

So darf es gern weiter gehen

[BikiniAnalyst]

Antwort auf Beitrag Nr.: 30.098.978 von klugerschachzug am 21.06.07 19:07:08

Also ich denke da genauso wie du!

Einer der reichsten Menschen der Welt sollte schon wissen in was er da eine Menge Kohle steckt. Und mit Biotech-Unternehmen hat er ja Erfahrung

[tsylver]

Antwort auf Beitrag Nr.: 30.143.769 von klugerschachzug am 22.06.07 10:47:52

Gute News, die sich anscheinend aber noch rumsprechen müssen...

[BikiniAnalyst]

Antwort auf Beitrag Nr.: 30.147.898 von tsylver am 22.06.07 14:14:31

Das ist bei Biotechs immer so ne sache...

Manchmal wirken sich News einfach aus wie ne bombe, manchmal garnicht und wieder ein anderes mal wirken sich die news erst mit der zeit nach und nach aus.

Ich denke aber bei Modigene steht alles auf einem soliden fundament

[BikiniAnalyst]

nochmal die Fakten:






Name: Modigene Inc.
Börsenkürzel Dtld: M3D
Kürzel USA: MODG
WKN: A0MSLD
ISIN: US6078261046
Anzahl der Aktien: 42,3 Mio.
Market Cap: 69,3 Mio. €

Kurs (19.06.2007): 1,64 € bzw. 2,20 US-$

Branche: Biotechnologie

Homepage: www.modigeneinc.com

-------------------------------------------------------

Dr. Philip Frost, der berühmte Biotechnologie-Magnat der im Jahr 2006 zu den 700 reichsten Menschen des Planeten gehörte und vor kurzem in Modigene investierte und diese mittels seiner Aufsichtsratposition auch berät, verkündete Mitte Mai
2007:
„Wir sind ganz aufgeregt über die Möglichkeiten durch Modigene und glauben an das Management-Team, den Produkten und der zugrunde liegenden Technologie. Wir freuen uns auf die Zusammenarbeit mit dem Management und dem Aufsichtsrat, um Modigene zu einem signifikanten Player im therapeutischen Proteinmarkt aufzubauen.“

------------------------

Modigene Inc. ist ein in der Stadt Vienna, Virginia (USA) beheimates Biotechnologie-Unternehmen (mit einer eigenen Forschungs-& Entwicklungs-Einrichtung namens ModigeneTech Ltd. im Weizmann Science Park in Nes Ziona, Israel), das mittels seiner exklusiv im Besitz befindlichen und patentierten Technologie therapeutische Proteine entwickelt, produziert und patentiert, die eine längere Lebensdauer besitzen und im Vergleich zu anderen Proteinprodukten seines Gleichen suchen.
Diese Produkte zielen auf den therapeutischen Proteinmarkt ab, der durch eine äußerst starke Nachfrage in den USA und Europa bekannt ist. Im Jahr 2005 kletterten die Verkaufseinnahmen in diesem Markt bereits auf $53 Mrd. an.

-------------------------

CHART USA


Mitte Mai 2007, direkt nach dem Börsengang von Modigene, wurde eine erfolgreich abgeschlossene Privatplatzierung an Wertpapieren bekannt gegeben, die Einnahmen von knapp $10 Mio. generierte, welche Mittel ausreichen dürften, die finalen Phasen der klinischen Tests und Produktzulassungen abzuschließen.

Die private Platzierung der Aktien fand zum Emissionskurs von $1,50 statt, währendhingegen die Warrants (Kaufoptionen von weiteren Aktien) zu einem Preis von $2,50 fixiert wurden und erst in 5 Jahren ausgeübt werden können. Das gesamte Management inklusive Mitglieder des Aufsichtsrats sowie 5% der Gesamtaktionäre haben eine Vereinbarung unterschrieben, ihre Wertpapiere nicht innerhalb der nächsten 18 Monate zu verkaufen. Dies zeigt deutlich, was das Management von Modigene hält und was es für die nächsten Monate und Jahre von diesem jungen (3 Wochen alt) Unternehmen erwartet (das allerdings bereits in einem fortgeschrittenen Stadium in der Entwicklung und Zulassung seiner Produkte steht).

[BikiniAnalyst]

MANAGEMENT

Das hochkarätige Management, das sich mittlerweile unter dem Dach von Medigene zusammengefunden hat, ist in der Branche allseits bekannt und konnte in der Vergangenheit bereits außergewöhnliche Erfolge feiern, wie z.B. Dr Abraham Havron (CEO), der für Merck Serono S.A. ein Multiple-Sklerose Medikament entwickelte und Merck bisher etwa $1,3 Mrd. einbringen konnte. Ferner entwickelte er auch ein bahnbrecherisches Hepatitis-B Impfungsmittel neben anderen bereits im Markt verfügbaren Medikamenten.
http://www.modigeneinc.com/AbrahamHavronMT.html

Dass Modigene die Meisterleistung erbringen konnte, sich die revolutionierende CPT Technologie direkt von der Washington University zu lizenzieren, hat enormes Aufsehen in der Branche bewirkt.

Es ist nur allzu verständlich, dass diese Lizenzen nun die besten Köpfe der Biotechnologie-Industrie anziehen, und so konnte
beispielsweise Mitte Mai 2007 verkündet werden, dass u.a. der bekannte Dr. Philip Frost nun im Aufsichtsrat von Modigene sitzt und selber auch neben der kürzlich stattgefundenen Privatplatzierung von etwa $10 Mio. in Modigene investiert hat.
Dr. Frost ist der ehemalige CEO & Vorstandsvorsitzende von IVAX Corp., welches Unternehmen 2006 für $7,4 Mrd. an Teva Pharmaceuticals verkauft wurde, und wo Dr. Frost mittlerweile als Vize-Vorstandsvorsitzender im Aufsichtsrat sitzt. Darüberhinaus ist Dr. Frost der CEO & Vorstandsvorsitzende von Opko Health Inc. (vorher Exegenics Inc) und Direktor von Northrop Grumman Corp. Im Jahr 2006 stand Dr Frost auf der Forbes Liste der reichsten Menschen der Welt auf Platz 645.

Die “ehemalige” Kollegin von Philip Frost, Dr Jane Hsiao (vormals Vize-Vorstandsvorsitzende für technische Angelegenheiten und CTO („Chief Technical Officer“) bei IVAX zwischen 1995 und 2006) sitzt nun ebenfalls im Aufsichtsrat von Modigene und investierte in das Unternehmen. Dr Hsiao war zwischen 1998 und 2006 auch
Vorstandsvorsitzende und Präsidentin von DVM Pharmaceuticals. Sie ist derzeit Direktorin der börsengelisteten Unternehmen Protalix BioTherapeutics Inc. und Opko Health Inc. Dr Hsiao besitzt darüberhinaus HSU Investments Ltd. und ist Großaktionärin vom
Charles Hsiao Family Trust-A und –B. Dr. Frost konnte daneben auch seine ehemaligen Kollegen aus der Zeit bei IVAX CORP, Steve Rubin (ehemaliger Senior Vize-Präsident und Chefsyndikus von IVAX) und Dr. Rao Uppaluri (ehemaliger Vize-Präsident der Strategischen Planung bei IVAX), überzeugen, ebenfalls in Modigene zu investieren.

------------------------------------


Hier mal der Chart von Opko Health Inc - Da ist Philip Frost CEO und Vorstandsvorsitzender!!






STEHT MODIGENE EINE ÄHNLICHE ENTWICKLUNG BEVOR ?????

[BikiniAnalyst]

Aktuell notiert die Aktie in den USA bei rund $2,20 und ist somit mit $93 Mio. bewertet. Bei einer Marktbewertung
von $1 Mrd. würde die Aktie bereits bei $23 stehen.

"Modigene besitzt eine exklusive Lizenz von der Washington University für alle Proteine (außer vier endokrine Proteine, welche an Organon lizenziert wurden). Der Pharmakonzern Schering-Plough kaufte am 13. März 2007 Organon für $14,4 Mrd. aufmerksam Modigene ist erst seit Mitte Mai 2007 börsengelistet, so dass Modigene mit seinen Lizenzen gar nicht aufgekauft werden konnte und mittels der starken und vom Management kontrollierten Aktionärsstruktur wohl auch nicht (feindlich) übernommen werden kann."

[tsylver]

man kann den kursverlauf nicht wirklich einordnen...

[manjasee]

Antwort auf Beitrag Nr.: 30.390.710 von tsylver am 29.06.07 13:05:56

wir befinden uns eben an der otc

[tsylver]

Press Release Source: Modigene Inc.


Key Trials of Organon's Long-Acting Fertility Drug Using Modigene's CTP Technology Achieve Clinical Trial Milestone
Monday July 2, 8:00 am ET
- Two Phase III Trials of Organon's FSH-CTP Product Reach Patient Randomization Target -
- These Trials are Expected to Reinforce the Clinical Utility of Modigene's CTP Technology -


VIENNA, Va., July 2 /PRNewswire-FirstCall/ -- Modigene Inc., (OTC Bulletin Board: MODG - News) today noted the achievement of an important milestone by Organon, a unit of Akzo Nobel NV, in two Phase III clinical trials being conducted for a long-acting fertility drug based on the same CTP platform technology being used by Modigene to extend the duration of action of other protein therapeutics. Organon announced on June 27, 2007 that two of its Phase III clinical trials with the investigational drug corifollitropin alfa (FSH-CTP), a long-acting fertility hormone based on the CTP technology, have reached their patient randomization target. Organon has rights to apply the CTP technology to four endocrine protein indications only, with all other applications of the CTP technology exclusively licensed to Modigene.

"The continued positive progress of the Phase III trials being conducted by Organon is very promising for the CTP platform technology for the development of superior long-acting protein therapeutics," said Shai Novik, President of Modigene. "One of the strengths of our CTP technology is that it appears to work with a wide variety of protein drugs and does so with similar results. The extended duration and clinical utility of Organon's FSH-CTP have already been demonstrated in previous clinical studies and we are optimistic that these positive attributes will be replicated in the clinical trials of our CTP-enhanced human growth hormone (hGH-CTP), interferon beta (IFN-Beta- CTP) and erythropoietin (EPO-CTP) products that Modigene expects to initiate next year."

Modigene is the exclusive licensee of Washington University for use of the CTP technology to create long-acting forms of protein and peptide therapeutic drugs. The only exception is FSH and three other endocrine proteins, which are exclusively licensed to Organon. Modigene's long-acting hGH-CTP, IFN- Beta-CTP and EPO-CTP have already successfully demonstrated significantly longer duration of effect and comparative biological efficacy in testing in industry-standard animal models.

Corifollitropin alfa (FSH-CTP) is a new long-acting recombinant fertility hormone based on a modified version of the recombinant follicle stimulating hormone (FSH). FSH is a hormone with approximately $1 billion in annual sales that is prescribed for women undergoing fertility treatments. In earlier studies Organon has shown that by linking the naturally-occurring peptide CTP to FSH, it can successfully extend the activity of the hormone, enabling a single injection of FSH-CPT to replace seven daily injections of standard FSH. These Phase lll trials are designed to test the clinical efficacy of FSH-CPT in a larger population and to provide the data needed for eventual marketing approval.

ABOUT CTP

Modigene's technology was discovered by researchers at Washington University in St. Louis, Missouri and is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in humans, and when attached to a therapeutic protein, extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Organon, which licenses the CTP technology for fertility applications only. Phase II trials of its CTP follicle stimulating hormone product (FSH-CTP) demonstrated that a single injection provides the same clinical effect as seven consecutive daily injections of standard FSH. These trials also demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. Modigene has an exclusive license from Washington University for use of CTP with all proteins except fertility hormones. Modigene is initially focusing on three CTP- enhanced compounds in preclinical development and is preparing to initiate clinical trials in 2008.

ABOUT MODIGENE

Modigene Inc. (OTCBB: MODG - News) is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. Modigene is currently developing long-acting versions of human growth hormone, erythropoietin, interferon beta, and GLP-1, which are in late pre-clinical development. For more information on Modigene, please visit www.modigeneinc.com.

Safe Harbor Statement

This press release contains forward-looking statements, including statements regarding the results of current studies and pre-clinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.


MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: [phone] [phone]
Email: [e-mail]


Source: Modigene Inc.

[Zocker_Freak]

Hält sich stabil um 2 $. Nächster Upmove könnte bevorstehen

[FREE_BUFFET]

bin auch durch BB auf dieses Unternhemen gekommen
anfangs recht skeptisch
aber jetzt hab ich mir die mal genauer angeschaut und bin beeindruckt
die werden bestimmt jetzt bald übernommen
freundliches angebot von einem großen kommt bestimmt

verstehe nur nicht was mit dem kurs los ist

aber denke, es sieht FAST danach aus, als ob vor kurzem ein Boden gefunden werden konnte in FFM

wie am chart sehen kann, ist der kurs aktuell mit 1,43 DIREKT unter dem roten widerstand bei 1,44. DIESER starke Widerstand muss gebrochen werden, wenn ein neuer Boom starten soll. also ein schliessen und halten über 1,45 wäre ein erstes kaufsignal (für mich). mal schaun, aber netter thread hier, danke für die vielen infos und meinungen insb. zu FROST den ich vorher gar nicht kannte

[FREE_BUFFET]

was mich ein wenig stutzig macht, ist warum dieses unternehmen keiner kennt und warum weltweit so wenig darüber geschrieben wird.

die proteine von Modigene befinden sich noch gar nicht in der klinischen phase am menschen nur die von organon ?

also dauerts noch ewig bis die Modigene-Produkte auf den markt kommen bzw. durch klinische Tests überhaupt verifiziert werden ??

[tsylver]

Modigene Prepares to Advance Its Long-Acting Human Growth Hormone Toward Clinical Trials via GMP Manufacturing Agreement
Monday July 16, 8:00 am ET
-Contract Manufacturer Xcellerex will Produce GMP hGH-CTP for Phase l Trials Projected to Begin Next Year-


VIENNA, Va., July 16 /PRNewswire-FirstCall/ -- Modigene Inc., (OTC Bulletin Board: MODG - News) today announced that it has signed a contract with Xcellerex, Inc., to provide GMP production of hGH-CTP, Modigene's long-acting human growth hormone (hGH), for upcoming preclinical studies and for the Phase I clinical trials projected to begin next year.

"We are pleased to be working with Xcellerex, a high quality contract bio- manufacturer, as we prepare for clinical trials of our lead hGH-CTP product that are targeted for next year," said Shai Novik, President of Modigene. "Human growth hormone was one of the earliest biotech drugs and remains among the most important for children, but it can require frequent injections. In preclinical studies, our long-acting hGH-CTP has demonstrated its potential to significantly decrease the frequency of these injections, which could provide important benefits for patients. We look forward to having the GMP material on hand to advance hGH-CTP toward clinical trials."

Human growth hormone is a natural protein produced by the pituitary gland in the brain. hGH fuels growth of the body's bone and muscle and has a variety of therapeutic uses. In patients with an hGH deficiency, current treatments involve subcutaneous hGH injections on a near-daily basis. Approximately 95% of children diagnosed with a growth hormone deficiency currently receive treatment, with costs ranging from $10,000 to $30,000 per year. In preclinical models, a single injection of hGH-CTP has shown the potential to replace 7 to 10 daily injections of commercial hGH.

Modigene's technology is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in humans, and when attached to a therapeutic protein, extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Organon, a unit of Akzo Nobel NV, which licenses the CTP technology for fertility applications only. Phase II trials of its CTP follicle stimulating hormone product (FSH-CTP) demonstrated that a single injection provides the same clinical effect as seven consecutive daily injections of standard FSH. These trials also demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. Modigene has an exclusive license from Washington University for use of CTP with all therapeutic proteins except fertility hormones. Modigene currently has four CTP-enhanced compounds in preclinical development and is preparing to initiate clinical trials in 2008.

Under the terms of the agreement, Xcellerex will produce enough hGH-CTP for further preclinical studies as well as for Phase I and Phase II clinical trials.

About Xcellerex

Xcellerex, Inc. provides next-generation manufacturing services and novel manufacturing systems for biotherapeutics and vaccines based on proprietary, single use, disposable component technology. Xcellerex's top quality contract manufacturing services include cell line creation, process development and GMP manufacturing. The company's products and technology include the FlexFactory(TM) manufacturing system, a complete, turnkey, modular production train; XDR(TM) stirred tank disposable bioreactor systems at 1,000L working volume; XDM(TM) stirred tank mixing systems, and PDMax(TM), a high throughput process development service platform. Xcellerex is based in Marlborough, MA. Learn more about Xcellerex at www.xcellerex.com.

ABOUT MODIGENE

Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. Modigene is currently developing long-acting versions of human growth hormone, erythropoietin, interferon beta, and GLP-1, which are in late preclinical development. For more information on Modigene, please visit www.modigeneinc.com.


Source: Modigene Inc.

[tsylver]

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

(c) Effective August 7, 2007, we hired Robert F. Mauer as the part-time Chief Financial Officer of Modigene Inc. (the “Company”).

Mr. Mauer, 53, is the Chief Financial Officer of Chicago Financial, Inc., a private company providing financial and administrative services to a variety of clients (including entities and individuals that are affiliated with Mr. Joel Kanter, an independent director of the Company). He has held that position since 2004. From 2001 to 2004 he was the CFO of Chicago Holdings, Inc., a private investment company specializing in private and public investments. From 1996 to 2000 he was the CFO of Walnut Financial, Inc. (NASDAQ: WNUT), a publicly-traded investment company that specialized in early-stage healthcare investments. From 1992 to 1996 he was Director of Corporate Planning, Vice President of Non-Utility Operations, and Controller of Non-Utility Operations for Washington Gas Light Company. From 1977 to 1992 he was employed by Owens Corning and held various financial positions including Controller of Owens Corning Great Britain. He is also a member of the Board of Directors of Thornton Friends School in Silver Spring, Maryland since July 2007.

During the last two years, there have been no transactions, or proposed transactions, to which the Company was or is a party, in which Mr. Mauer had or is to have a direct or indirect material interest.


(e) On August 7, 2007, Mr. Mauer and the Company entered into an Employment Agreement (the “Agreement”) reflecting the terms and conditions of his part-time employment with the Company.

Pursuant to the Agreement, Mr. Mauer will serve as our Chief Financial Officer on a part-time basis, and will undertake the principal financial officer function of the Company. The Agreement provides for a monthly salary of $3,666.67 to Mr. Mauer, together with reimbursement of reasonable out-of-pocket expenses incurred by Mr. Mauer in the course of his employment. Mr. Mauer is not entitled to participate in any welfare or benefit plans generally made available to full time employees of the Company. The Agreement is an at-will agreement, terminable by either the Company or Mr. Mauer on 30 days’ notice. The Agreement may also be terminated by the Company in the event of a breach by Mr. Mauer, but if such breach is curable Mr. Mauer will have 30 days following notice in which to cure the breach. In the event of any termination of the Agreement, Mr. Mauer will be entitled only to salary accrued through the date of termination. The Agreement contains a customary agreement by Mr. Mauer relating to non-disclosure of confidential information.

The foregoing description of the Agreement is qualified in its entirety by reference to the provisions of the Agreement attached to this Current Report as Exhibit 10.1.

[tommster82]

Schaut mal auf firstcapitalresearch.com
Da gibt ne schöne studie

[tsylver]

MODIGENE TO PRESENT AT THE ROTH 2007 NEW YORK INVESTOR CONFERENCE--Presentation to Be Webcast Live and Archived--
VIENNA, VA August 29, 2007 -- Modigene Inc. (OTCBB: MODG) today announced that
senior management will present at the Roth 2007 New York Investor Conference on
Thursday, September 6, 2007 at 3:00 pm EDT. The conference will be held at the Westin
New York at Times Square in New York City.
Modigene CEO Abraham Havron and President Shai Novik will provide a company overview
and review of corporate developments.
“As a relatively new public company, we look forward to this opportunity to inform additional
investors about our innovative technology that has the potential to significantly extend the
duration of virtually any therapeutic protein drug,” noted Dr. Havron. “We believe our
product pipeline has great clinical and commercial promise as a result of our ability to
increase the utility and convenience of a wide range of protein therapeutics currently used by
millions of patients each year.”
The Modigene presentation will be webcast live and can be accessed by visiting
www.wsw.com/webcast/roth13/modigene/. An archived version of the presentation webcast
will also be available following the conclusion of the conference at the same address for
approximately 90 days.
For more information about the Roth 2007 New York Investor Conference, visit
www.roth.com/main/Page.aspx?PageID=7015.
ABOUT MODIGENE
Modigene Inc. (OTCBB:MODG) is a biopharmaceutical company applying its patented CTP
technology to develop longer-acting, proprietary versions of already approved therapeutic
proteins that currently generate billions of dollars in annual global sales. Modigene is
currently developing long-acting versions of human growth hormone, erythropoietin,
interferon beta, and GLP-1, which are in late preclinical development. For more information
on Modigene, please visit www.modigeneinc.com.
Safe Harbor Statement: This press release contains forward-looking statements, including
statements regarding the results of current studies and preclinical experiments and the
effectiveness of Modigene’s long-acting protein programs and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned
that forward-looking statements involve risks and uncertainties that may affect Modigene’s
business and prospects, including the risks that Modigene may not succeed in developing any
commercial products based upon its long-acting protein technology, including any long-acting
versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting
products in development may fail, may not achieve the expected results or effectiveness and/or
may not generate data that would support the approval or marketing of these products for the
indications being studied or for other indications; that ongoing studies may not continue to show
substantial or any activity; and other risks and uncertainties that may cause results to differ
materially from those set forth in the forward-looking statements. The development of any products
using the CTP platform technology could also be affected by a number of other factors, including
unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses anddecision making, the impact of pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In
addition to the risk factors set forth above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in Modigene’s filings with the Securities
and Exchange Commission.
MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: [phone] [phone]
Email: [e-mail]

[tsylver]

Antwort auf Beitrag Nr.: 31.346.146 von tsylver am 30.08.07 18:13:58

da bin ich ja mal gespannt...

[tsylver]

so hoch war das Volume schon seit drei Monaten nicht mehr...

vielleicht liegt es ja an der morgen beginnende Roth 2007 New York Investor Conference.

Ob da schon vorher gekauft wird?

[tsylver]

Antwort auf Beitrag Nr.: 31.408.879 von tsylver am 05.09.07 23:34:20

nochmal 50% mehr Volume!

wirkt die "Roth 2007 New York Investor Conference" schon?

auf einen baldigen Anstieg

[tsylver]

Source: Modigene Inc.


Modigene to Present at UBS 2007 Global Life Sciences Conference
Tuesday September 18, 8:00 am ET


VIENNA, Va., Sept. 18 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG - News) today announced that senior management will present at the UBS 2007 Global Life Sciences Conference on Wednesday, September 26, 2007 at 12:00 pm EDT. The conference will be held at the Grand Hyatt New York in New York City.

Modigene CEO Abraham Havron and President Shai Novik will attend. Management will provide a company overview and review of corporate developments.

The audio portion of the company's presentation will be webcast live. It can be accessed at the Investors section of the Modigene website at www.modigeneinc.com. An archived version of the webcast will be available for 30 days beginning three hours after the start of the presentation. The live and archived audio webcast can also be accessed at the UBS website at
http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20…

For more information about the UBS 2007 Global Life Sciences Conference, visit
www.presentationsmedia.com/globallifesciencesev/about.html.

ABOUT MODIGENE

Modigene Inc. (OTC Bulletin Board: MODG - News) is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long- acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.


MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: [phone] [phone]
Email: [e-mail]

Source: Modigene Inc.

[tsylver]

Press Release Source: Modigene Inc.


Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
Monday September 24, 7:00 am ET
- Publication in Leading Peer-Reviewed Journal Represents Further Scientific Validation of the Potential Utility of Modigene's CTP Technology -


VIENNA, Va., Sept. 24 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG - News) today reported that researchers will publish a study in the October edition of the journal Endocrinology showing that erythropoietin (EPO) linked to Modigene's carboxyl terminal peptide (CTP) technology significantly increased the half-life of standard EPO in animal models.(1) The study, which assessed an early version of EPO-CTP, showed that a single weekly injection was as effective in raising hematocrit levels as the same total dose of standard EPO administered in three injections over the course of a week.

The current version of EPO-CTP in preclinical development at Modigene has further extended the duration of the drug, demonstrating in animal models an approximately 33% longer half-life and greater biological activity than Aranesp®, Amgen's long-acting EPO.

"The publication of this study in the respected journal Endocrinology further validates the growing body of clinical and preclinical data supporting the ability of CTP technology to significantly extend the half-life and duration of action of therapeutic proteins," said Dr. Fuad Fares, lead author of the study and Chief Scientific Officer of Modigene. "Long-acting therapeutic protein drugs are increasingly important treatments for a variety of diseases, and we believe the demonstrated ability of our CTP technology to reduce the frequency of required injections could provide important benefits to the many patients who depend on these drugs. We look forward to advancing our first CTP-enhanced drug candidates into clinical trials next year."

Modigene is conducting late-stage preclinical studies of CTP-enhanced protein drugs including human growth hormone, interferon beta and EPO. All three have demonstrated significantly longer duration of effect and comparative biological efficacy in studies in the most common and relevant animal models. The CTP technology has been validated in human studies by Akzo Nobel's healthcare division, Organon International, which has rights to the technology for four endocrine proteins. Organon recently advanced its CTP follicle-stimulating hormone (FSH) product into Phase III trials after Phase II studies showed that a single injection provided the same clinical effect as seven daily injections of standard FSH.

ABOUT CTP

Modigene's technology was discovered by researchers at Washington University in St. Louis and is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in humans, and when attached to a therapeutic protein, extends the time that the protein is active in the body. The potential clinical utility of the technology has been demonstrated by Organon International, a unit of Akzo Nobel, which has a license to the CTP technology for certain endocrine proteins. Organon recently initiated Phase III trials of its CTP follicle stimulating hormone product (FSH-CTP), after Phase II results demonstrated that a single injection of FSH-CTP provides the same clinical effect as seven consecutive daily injections of standard FSH. The Phase II trials also demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response.


1. Development of a Long-Acting Erythropoietin by Fusing the Carboxyl-
Terminal Peptide of Human Chorionic Gonadotropin b-Subunit to the
Coding Sequence of Human Erythropoietin," Fuad Fares, Sherif Ganem,
Taleb Hajouj, and Ester Agai, Endocrinology 148(10):5081-5087. The
study is currently available in the on-line edition of the journal.

ABOUT MODIGENE

Modigene Inc. (OTC Bulletin Board: MODG - News) is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long- acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.


MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: [phone] [phone]
Email: [e-mail]

Source: Modigene Inc.

[tsylver]

Modigene Inc. 8000 Towers Crescent Drive, Suite 1300, Vienna, VA 22182 1
MODIGENE TO PRESENT AT ACUMEN BIOFIN RODMAN & RENSHAW
9th ANNUAL HEALTHCARE CONFERENCE
VIENNA, VA November 1, 2007 -- Modigene Inc. (OTCBB: MODG) today announced that
senior management will present at the Acumen BioFin Rodman & Renshaw 9th Annual
Healthcare Conference on Wednesday, November 7, 2007 at 1:40 pm ET. The conference
will be held at the New York Palace Hotel in New York City.
Modigene CEO Abraham Havron and President Shai Novik will attend. Management will
provide a company overview and review of corporate developments.
The presentation will be webcast live and can be accessed by visiting the Investors section
of the Modigene website at www.modigeneinc.com. An archived version of the webcast will
be available for approximately 90 days. The live and archived webcast can also be
accessed at www.wsw.com/webcast/rrshq12/modg.ob.
For more information about this conference, visit:
www.rodmanandrenshaw.com/conferences?id=6
About Modigene
Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to
develop longer-acting, proprietary versions of already approved therapeutic proteins that
currently generate billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins and Modigene is currently developing long-acting versions
of human growth hormone, interferon beta and erythropoietin, which are in late preclinical
development, as well as GLP-1. For more information on Modigene, visit
www.modigeneinc.com .
MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: [phone] [phone]
Email: [e-mail]

[tsylver]

13-Nov-2007

Quarterly Report


http://biz.yahoo.com/e/071113/modg.ob10qsb.html

[tsylver]

Press Release Source: Modigene Inc.


Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Human Growth Hormone
Tuesday November 27, 8:36 am ET

- $10 Million hGH-CTP Development Program has Been Approved for Funding Through a Special Grant from the Israeli Office of The Chief Scientist -


VIENNA, Va., Nov. 27 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG - News) today reported that its Israeli-based R&D subsidiary has received approval for a special grant from the Israeli Office of the Chief Scientist ("OCS") in support of the company's development program for hGH-CTP, its longer-acting version of human growth hormone (hGH). In preclinical models, a single injection of hGH-CTP has shown the potential to replace 7 to 10 daily injections of commercial hGH.


The OCS has approved a special grant to support Modigene's hGH-CTP program, based on an estimated development budget of $10 million for calendar years 2007-2009. The grant will provide cash reimbursements of 30% to 50% of expenses paid for hGH-CTP product development during this period, including materials, GMP production, salaries and clinical trials. hGH-CTP is currently in preclinical development, with clinical trials expected to begin in 2008.

Human growth hormone is a natural protein produced by the pituitary gland in the brain. It fuels growth of the body's bone and muscle and has a variety of therapeutic uses. Patients with an hGH deficiency currently receive subcutaneous hGH injections on a near-daily basis. Approximately 95% of children diagnosed with a growth hormone deficiency receive treatment, with costs ranging from $10,000 to $30,000 per year. The current annual market for hGH therapies exceeds $2 billion.

"This generous new grant from the OCS is an important non-dilutive cash resource for Modigene and represents another validation of the potential of our lead candidate," said Abraham Havron, Ph.D., Chief Executive Officer of Modigene. "The OCS has already awarded Modigene funds in support of our EPO- CTP product candidate and we are delighted that our hGH-CTP program has now also been selected for support. This visionary OCS program is particularly attractive for Modigene because it does not require any repayment until the product is generating revenue. We are grateful for this valuable source of non-dilutive capital."

Under the terms of the grant, Modigene shall repay the OCS the sum of the grant plus accrued interest through a series of payments that begin only upon successful commercialization of the hGH-CTP product, or other products developed at the company with its CTP technology.

Modigene's technology is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in humans, and when attached to a therapeutic protein, extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Organon, a unit of Schering-Plough, which licenses the CTP technology for fertility applications only. Phase II trials of its CTP follicle stimulating hormone product (FSH-CTP) demonstrated that a single injection provides the same clinical effect as seven consecutive daily injections of standard FSH. These trials also demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. Modigene has an exclusive license from Washington University for use of CTP with all therapeutic proteins except four fertility proteins. Modigene currently has three CTP-enhanced compounds in preclinical testing and a fourth in earlier stage development.

ABOUT MODIGENE

Modigene Inc. (OTCBB: MODG - News) is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit http://www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long- acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from the OCS is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.


MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: [phone] [phone]
Email: [e-mail]

Source: Modigene Inc.

[tsylver]

nach langem Abwärtstrend heute mal ein plus von 23%.

ist dies die trendwende?

[tsylver]

Antwort auf Beitrag Nr.: 32.833.309 von tsylver am 20.12.07 23:29:42

und heute wieder plus 25%. nicht schlecht...

[tsylver]

Change in Directors or Principal Officers

Form 8-K for MODIGENE INC.

4-Jan-2008

Change in Directors or Principal Officers

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) On December 30, 2007, Mr. Alastair Clemow delivered written notice to Modigene Inc. (the "Company"), stating that he was resigning from his position as a member of the Board of Directors of the Company effective January 1, 2008. Mr. Clemow resigned for personal reasons.

Effective December 21, 2007, Mr. Clemow also tendered his resignation as a member of the Compensation Committee of the Board of Directors. In addition, prior to his resignation from the Board, Mr. Clemow served as a member of the Audit Committee.

[Peederwoogn2]

Antwort auf Beitrag Nr.: 30.015.243 von BikiniAnalyst am 19.06.07 11:20:21

na immer noch alles klar

[tsylver]

Modigene Announces Appointment of Dr. Phillip Frost as Chairman of Its Board of Directors
Wednesday March 5, 8:00 am ET
-In Other Board Changes, Two Pharmaceutical Industry Veterans Join to Fill Vacancies Created by Recent Departures-


NES-ZIONA, Israel, March 5 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG - News) today announced the appointment of Phillip Frost, M.D., as Chairman of its Board of Directors. Modigene also announced the appointments of two new directors, Dr. Marian Gorecki and Steven D. Rubin, and the departures of current Board Chairman and director Dr. Eugene Bauer and current director Joel Kanter.

"The addition of Dr. Frost as Chairman and Dr. Gorecki and Mr. Rubin as directors is a very positive development for Modigene," said Avri Havron, CEO of Modigene. "As the company now transitions into a clinical stage biopharmaceutical company, we believe the enhanced commitment of Dr. Frost and the diverse, real-world clinical and commercial experience that he, Dr. Gorecki and Mr. Rubin bring will be of great value to Modigene and its shareholders."

Dr. Frost has been a member of the Modigene Board of Directors since May 2007.

"After working closely with the Modigene team as a director over the past year, I am very pleased to be expanding my involvement in the company at this exciting time in its development," said Dr. Frost. "In my new role as Chairman, I look forward to providing further leadership in working with the Board and management to build Modigene into a significant player in the therapeutic proteins market."

Dr. Frost currently serves as Chairman and CEO of OPKO Health, Inc., a publicly-traded specialty healthcare company. He also serves as Chairman of Ladenburg Thalmann & Co. Inc., as Vice Chairman of Teva Pharmaceuticals, and as a director of Northrop Grumman Corporation and Continucare Corporation. He is a trustee of the University of Miami, the Scripps Research Institute, the Miami Jewish Home for the Aged and the Mount Sinai Medical Center; a regent of the Smithsonian Institute, and Vice Chairman of the Board of Governors of the American Stock Exchange. Previously, Dr. Frost was Chairman and CEO of IVAX Corporation, which he founded in 1987, until the company's acquisition by Teva Pharmaceuticals in 2006. Dr. Frost holds a B.A. from the University of Pennsylvania and an M.D. degree from the Albert Einstein College of Medicine.

Dr. Marian Gorecki, a 30-year veteran of the biotechnology industry, is currently Chairman of Thrombotech, a company developing a peptide to mitigate the side effects of standard stroke treatments. Previously, Dr. Gorecki co- founded and served as General Manager and Board member of Bio Technology General (BTG), now Savient Pharmaceuticals Inc. He also served as Chairman and CEO of Mediwound Ltd., a biotechnology company developing enzyme-based products in the fields of burn and wound management. Dr. Gorecki was responsible for overseeing the clinical development, regulatory approval and commercialization of five biotechnology drugs that are currently marketed, as well as two that are now in Phase III trials. Dr. Gorecki is the inventor of 21 issued patents and author of 73 peer-reviewed scientific articles. He earned his Ph.D. in biochemistry and molecular biology from the Weizmann Institute of Science and served as a Research Fellow at the Massachusetts Institute of Technology.

Steven D. Rubin, J.D., is currently Executive Vice President- Administration and a director of OPKO Health, Inc. He currently also serves as a director of SafeStitch Medical Inc., a medical device company, of Dreams Incorporated, a manufacturer and provider of licensed sports products, of Ideation Acquisition Corp., a special purpose acquisition company, and of Longfoot Communications Corp. Previously, he was Senior Vice President and General Counsel of IVAX. Prior to IVAX, Mr. Rubin was Senior Vice President and General Counsel of Telergy Inc. Mr. Rubin holds a B.A. from Tulane University and a J.D. degree from the University of Florida, Gainesville.

Dr. Frost added, "On behalf of the Board, we also want to thank Dr. Eugene Bauer and Joel Kanter for their many past contributions as Board members of Modigene." Dr. Bauer and Mr. Kanter have submitted their resignations from the Modigene Board to pursue other personal and professional interests.

Modigene's technology is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in humans, and when attached to a therapeutic protein, extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Organon, a unit of Schering-Plough, which licenses the CTP technology for fertility applications only. Phase II trials of its CTP follicle stimulating hormone product (FSH-CTP) demonstrated that a single injection provides the same clinical effect as seven consecutive daily injections of standard FSH. These trials also demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. Modigene has an exclusive license from Washington University for use of CTP with all therapeutic proteins except four fertility proteins. Modigene currently has three CTP-enhanced compounds in preclinical testing and a fourth in earlier stage development.

ABOUT MODIGENE

Modigene Inc. (OTC Bulletin Board: MODG - News) is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit www.modigeneinc.com.

[tsylver]

6-Mar-2008

Termination of a Material Definitive Agreement, Change in Directors or Principal Of
Item 1.02 Termination of a Material Definitive Agreement.
(a) As disclosed in Item 5.02 below, effective March 4, 2008, Robert F. Mauer, the part-time Chief Financial Officer and principal financial officer of Modigene Inc. (the "Company"), resigned. At the time of his resignation, his employment agreement with the Company was terminated by the mutual agreement of the parties with no further liability of either party, other than the payment by the Company of Mr. Mauer's salary through the effective date of his resignation.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) On February 29, 2008, each of Dr. Eugene Bauer and Mr. Joel Kanter delivered written notice to Modigene Inc. (the "Company") stating that he was resigning from his position as a member of the Board of Directors of the Company effective February 29, 2008. Each of Dr. Bauer and Mr. Kanter resigned for personal reasons.

Effective March 4, 2008, Robert F. Mauer, resigned as the Company's part-time Chief Financial Officer and principal financial officer.

(c) On March 4, 2008, Mr. Steven D. Rubin and Mr. Marian Gorecki were appointed to the Board of Directors of the Company. Mr. Rubin and Mr. Gorecki were appointed by the remaining current members of the Board (Dr. Abraham (Avri) Havron, Mr. Shai Novik, Dr. Fuad Fares, Dr. Phillip Frost, Dr. Jane Hsiao and Mr. Adam Stern) pursuant to Section 4 of Article II of the Company's amended and restated bylaws, which allows the Company's directors to fill any vacancy in the Board.

Mr. Rubin was also appointed to serve on the Audit and Compensation Committees of the Board of Directors and in addition was appointed as chairman of the Audit Committee and was designated as the "audit committee financial expert" as defined in the Securities Exchange Act of 1934, as amended. Mr. Gorecki was appointed to serve on the Audit, Compensation and Governance Committees of the Board of Directors.

On May 9, 2007, simultaneously with the Company's closing of its acquisition of Modigene Inc., a Delaware corporation, the Company sold a total of 5,377,660 shares of its common stock, plus warrants to purchase 333,333 shares of common stock, to four strategic investors led by Dr. Phillip Frost and Dr. Jane Hsiao, who were appointed as directors upon the closing of merger and related transactions, for total consideration of US$2,000,000. On May 21, 2007, the Company issued an additional 155,673 shares of common stock for no additional consideration to these investors, for a total of 5,533,333 shares issued to this investor group. Mr. Rubin was one of the investors participating in this transaction, and he individually purchased a total of 27,666 shares, and warrants to purchase an additional 1,666 shares, of common stock in this offering, for total consideration of US$10,000.

At the time of his appointment to the Board of Directors, Mr. Gorecki was awarded an option to purchase 25,000 shares of common stock of the Company at an exercise price of $0.93. The options vest in equal annual installments over a three-year period, and will expire ten years from the date of grant. These options were awarded under the Company's 2007 Equity Incentive Plan.

In connection with the changes to the Company's Board of Directors discussed above, the Board appointed Dr. Phillip Frost as Chairman of the Board.

Effective March 5, 2008, we engaged Mr. Steve Schaeffer as Chief Financial Officer and the principal financial officer of the Company. Mr. Schaeffer, 58, has over 30 years of accounting and tax experience. He is a principal and founder of Cohen & Schaeffer, P.C., a full service CPA firm co-founded by Mr. Schaeffer in 1993. Prior to forming Cohen & Schaeffer, Mr. Schaeffer was a tax partner at BDO Seidman and a principal at Laventhol & Horwath. Mr. Schaeffer has no family relationships with any director or executive officer of the Company. During the last two years, there have been no transactions, or proposed transactions, to which the Company was or is a party, in which Mr. Schaeffer had or is to have a direct or indirect material interest.

(e) On February 29, 2008, the Compensation Committee approved amendments to the employment and consulting agreements between the Company and each of Dr. Abraham (Avri) Havron, its Chief Executive Officer, and Mr. Shai Novik, its President. Also on that date, ModigeneTech Ltd., a wholly-owned subsidiary of the Company, entered into an amendment of its Employment Agreement with Dr. Eyal Fima.

Under his amended consulting agreement, (i) Dr. Havron's annual consulting fee has been increased from US$140,000 to US$215,000, effective retroactively to January 1, 2008, (ii) the structure of his potential performance bonus has been changed from up to 25% of his annual consulting fee to up to US$60,000 (approximately 28% of his new annual consulting fee), and (iii) Dr. Havron has been granted the use of a Company car.

Under Mr. Novik's amended employment agreement, (i) his annual base salary has been increased from US$205,000 to US$250,000, effective retroactively to January 1, 2008, (ii) his performance bonus parameters have been changed from up to 50% of his annual base salary to up to US$85,000 (34% of his annual base salary), and (iii) Mr. Novik has been granted the use of a Company car.

Dr. Fima's amended employment agreement increases his annual base salary from NIS 300,000 (approximately US$82,800 at the current conversion rate) to US$100,000, effective retroactively to January 1, 2008, and increases his potential maximum performance bonus from 25% of his annual base salary to 50% of his annual base salary.

On February 29, 2008, the Compensation Committee of the Board of Directors approved cash performance bonuses for the 2007 fiscal year as follows: (i) Dr. Havron was granted a performance bonus of US$60,000, which included a US$25,000 bonus granted pursuant his consulting agreement and a special bonus of US$35,000 awarded by the Compensation Committee in recognition of Dr. Havron's work in accomplishing the preclinical development milestone's for the Company's drug candidates, while conserving cash and ending the year significantly under budget; and (ii) Dr. Fima was granted a performance bonus of US$37,500, which included US$20,000 pursuant to his employment agreement, and a special bonus of US$15,500 awarded by the Compensation Committee in recognition of Dr. Fima's work in accomplishing the preclinical development milestones for the Company's drug candidates, while conserving cash and ending the year significantly under budget.


On March 5, 2008, Mr. Schaeffer, Cohen & Schaeffer LLP ("CS") and the Company entered into an Agreement (the "Agreement") reflecting the terms and conditions of Mr. Schaeffer's engagement with the Company.

Pursuant to the Agreement, Mr. Schaeffer will serve as the Company's Chief Financial Officer and the designated principal financial officer on a part-time basis, and CS and Mr. Schaeffer will provide services to the Company including creating and maintaining sound accounting policies and procedures, managing books and records, preparing and reviewing quarterly and financial statements as well as reviewing the Company's financial and disclosure controls and procedures. The Agreement provides for a quarterly payment of $12,000 to CS, together with reimbursement of reasonable out-of-pocket expenses incurred by CS or Mr. Schaeffer in the course of service to the Company. Mr. Schaeffer is not entitled to participate in any welfare or benefit plans generally made available to full time employees of the Company. The Agreement is for a two-year period and may be extended by the mutual agreement of the parties for additional subsequent 12-month periods, and may be earlier terminated by either the Company or Mr. Schaeffer and CS on 30 days' notice. The Agreement may also be terminated by the Company in the event of a breach by Mr. Schaeffer or CS, but if such breach is curable Mr. Schaeffer and CS will have 30 days following notice in which to cure the breach. In the event of any termination of the Agreement, CS will be entitled only to payments accrued through the date of termination. The Agreement contains a customary agreement by Mr. Schaeffer and CS relating to non-disclosure of confidential information. The foregoing description of the Agreement is qualified in its entirety by reference to the provisions of the Agreement attached to this Current Report as Exhibit 10.1.

Item 9.01 Financial Statements and Exhibits.
(c) Exhibits


Exhibit No. Description

10.1 Agreement among Modigene Inc., Cohen &
Schaeffer LLP and Steve Schaeffer (filed
herewith)

[tsylver]

Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
Thursday March 27, 8:00 am ET
- Financing Includes Equity Investment and Line of Credit -

NES-ZIONA, Israel, March 27 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG - News), a biopharmaceutical company applying its patented technology to develop longer-acting versions of already-approved therapeutic proteins, today announced that it has closed a $2 million equity investment by a group of private investors and has entered into a line of credit agreement that provides for the availability of an additional $10 million financing. The equity investors consist of a group led by Dr. Phillip Frost, who is also the Chairman of the Board of Modigene, and the line of credit has been extended by The Frost Group LLC. Two other directors of Modigene, Dr. Jane Hsiao and Steven Rubin, are participants in the equity financing and are members of The Frost Group.

In the equity financing, Modigene issued a convertible series A preferred security at a price of $2.50 per preferred share and under the line of credit it received an option to borrow up to $10 million at an interest rate of 10% per annum that includes warrant coverage if utilized.

"Protein therapeutics represent an increasingly significant segment of the biopharmaceutical market, and we believe that Modigene's unique technology has great potential to deliver the longer-acting drugs sought by patients and their health providers," said Dr. Frost. "We welcome this opportunity to further support this promising company."

The convertible series A preferred security automatically converts into Modigene unregistered common stock after four years at a price that will be set depending on the company's market capitalization at that time. The price targets are structured to offer more favorable terms to the investors if the company is able to significantly increase its market capitalization by at least four times during this period - a market capitalization that would benefit all shareholders.

"This financing is a winning combination for Modigene and its shareholders," said Avri Havron, CEO of Modigene. "It provides the company with an immediate $2 million in cash and an option to borrow up to another $10 million at very attractive terms. We believe that Modigene's current cash position, our anticipated cash grants from the Israeli government for our human growth hormone program and the option for a $10 million five-year loan provide us with a robust capital structure. We anticipate that these resources will be sufficient to enable us to complete Phase II clinical studies for our two most advanced long-acting protein therapeutics and also provide us with at least three years of operating cash."

The line of credit extended by The Frost Group is initially for a one-year period. If Modigene draws down cash from the line of credit during the one-year period, Modigene will issue to The Frost Group 1.5 million warrants to purchase unregistered common stock of the company. The warrants have a five-year term and a $0.99 exercise price. Although the line of credit is secured, the intellectual property of the company is not part of any lien or security provided to The Frost Group under the line of credit.

"The attractive terms of this financing further demonstrate the strong commitment of the Frost investor group to Modigene," added Mr. Havron. "The structure of the transaction is well-aligned with the interests of all our shareholders. We view the option to borrow up to $10 million at favorable terms an important strategic advantage for a preclinical stage biotechnology company such as Modigene, providing management and our shareholders with the flexibility of significant potential leverage."

For more information on the financing, visit the SEC filings link at our website at www.modigeneinc.com.

[tsylver]

Form 8-K for MODIGENE INC.

27-Mar-2008

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati
Item 1.01 Entry into a Material Definitive Agreement.
On March 25, 2008, Modigene Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with Frost Gamma Investments Trust (the "Frost Trust"), Jane Hsiao, M.B.A., Ph. D., Steven D. Rubin, and Subbarao Uppaluri (collectively, the "Investors"). Dr.Phillip Frost, the Chairman of our board of directors, is the sole trustee of the Frost Trust. Frost Gamma, L.P. is the sole and exclusive beneficiary of the Frost Trust, and Dr. Frost is one of two limited partners of Frost Gamma, L.P. The general partner of Frost Gamma, L.P. is Frost Gamma, Inc. and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr.Frost is the sole stockholder of Frost-Nevada Corporation. Dr. Hsiao and Mr. Rubin are also directors of Modigene.

The Securities Purchase Agreement provides that the Company will sell to the Investors, and the Investors will purchase from the Company, 800,000 shares of Series A preferred stock, $0.00001 par value per share (the "Series A Preferred Stock"), at $2.50 per share, for an aggregate purchase price of $2,000,000. Of the 800,000 shares of Series A Preferred Stock purchased under the Securities Purchase Agreement, the Frost Trust purchased 632,000 shares for $1,580,000, Dr. Hsiao purchased 152,000 shares for $380,000 and Mr. Rubin purchased 8,000 shares for $20,000.

The rights and preferences of the Series A Preferred Stock are described in Item 3.03 below.

On March 25, 2008, the Company also entered into a line of credit with The Frost Group, LLC, as described under Item 2.03 below.

A copy of a Press Release, dated March 27, 2008, issued by the Company relating to the issuance of the Series A Preferred Stock and the entry into the line of credit is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
(a) On March 25, 2008, simultaneously with the closing of the transaction under the Securities Purchase Agreement, the Company entered into a Credit Agreement and a Note and Security Agreement with The Frost Group, LLC ("TFG"), a Florida limited liability company whose members include the Frost Trust, Dr. Hsiao and Mr. Rubin.

Under this line of credit, the Company may, at its discretion, borrow up to $10,000,000, which proceeds may be used for working capital or general corporate purposes of the Company, as approved by our board of directors. The maturity date for the line of credit is March 25, 2009, unless (i)the Company has borrowed any funds under the line of credit prior to March 25, 2009, or (ii)the Company elects to extend the line of credit. In either of such events the maturity date will be extended until March 25, 2013. Upon the maturity date, as the same may be extended, the Company is obligated to repay to TFG all outstanding borrowings, together with any accrued interest, and the line of credit will terminate. The Company is obligated to pay interest on outstanding borrowings under the line of credit at a 10% annual rate. In the event the Company determines to draw on the line of credit, or the Company elects to extend the maturity date until March 25, 2013, the Company will issue to TFG 5-year warrants (the "TFG Warrants") to purchase 1,500,000 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), having an exercise price of $0.99 per share.

Item 3.02 Unregistered Sales of Equity Securities.
(a) On March 25, 2008, the Company issued 800,000 shares of the Series A Preferred Stock as described in Item 1.01 above. In addition, the Company may become obligated to issue the TFG Warrants as described in Item 2.03 above. The terms of conversion of the Series A Preferred Stock are described in Item 3.03 below, and the terms of exercise of the TFG Warrants are described in Item 2.03 above.

None of the Series A Preferred Stock, the TFG Warrants or the Common Stock issuable in connection with any conversion of the Series A Preferred Stock or exercise of the TFG Warrants will be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws, and will be issued to the Investors pursuant to the exemption from registration under
Section 4(2) of the Securities Act and Rule 506 of Regulation D as promulgated by the Securities and Exchange Commission. No general solicitation was made by us or any person acting on our behalf with respect to the issuance of the Series A Preferred Stock to the Investors or with respect to the issuance of the TFG Warrants to TFG. The Series A Preferred Stock and the TFG Warrants are being issued pursuant to transfer restrictions, and the certificates for shares of Series A Preferred Stock and any warrant certificate representing the TFG Warrants will contain appropriate legends stating that such securities are not registered under the Securities Act and may not be offered or sold absent registration or an exemption from registration. Each of the Investors and TFG is an "accredited investor," as that term is defined by Rule 501 of Regulation D under the Securities Act.

Item 3.03 Material Modification to Rights of Security Holders.
(a) In connection with the Securities Purchase Agreement described in Item 1.01 above, the Company has approved the designation of 800,000 shares of its preferred stock as the Series A Preferred Stock. The following is a summary of material provisions of the Series A Preferred Stock, the terms of which are set forth in detail in the Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the "Certificate of Designations") filed with the Secretary of State of the State of Nevada upon the consummation of the transactions under the Securities Purchase Agreement. The Certificate of Designations is attached to this Report as Exhibit 4.1.

Right to Convert. Each holder of shares of Series A Preferred Stock shall be entitled, at the option of such holder, to convert all, but not less than all, of the shares of Series A Preferred Stock then held by such holder, at any time and from time to time beginning on March 1, 2009 and ending at 5:00 p.m., Eastern time, on March 25, 2012 (the "Conversion Deadline"), without the payment of any additional consideration, into Common Stock at the applicable conversion price discussed below.

Automatic Conversion. If any holder of shares of Series A Preferred Stock has not exercised his, her or its right to convert the shares of Series A Preferred Stock then held by such holder on or prior to the Conversion Deadline, then at the Conversion Deadline all such shares of Series A Preferred Stock will automatically convert, without the payment of any additional consideration, into Common Stock at the applicable conversion price discussed below.

Conversion Ratio. Each holder of Series A Preferred Stock may, at such holder's option, convert all, but not less than all, of his shares of Series A Preferred Stock into shares of our Common Stock, at any time and from time to time, without the payment of any additional consideration. Each share of Series A Preferred Stock is convertible into our Common Stock based upon a conversion ratio equal to (x) the $2.50, divided by (y) the conversion price in effect at the time of conversion, which conversion price is subject to adjustment as set forth below. The conversion price will initially be $2.50. Accordingly, the initial conversion ratio will be one share of Common Stock for one share of Series A Preferred Stock.

The conversion price will change in the event that a Market Capitalization Contingency occurs. A "Market Capitalization Contingency" shall occur if the aggregate market value of the Common Stock, obtained by multiplying (a) the number of shares of Common Stock outstanding (on a fully-diluted basis, as follows: taking into account the shares of Common Stock issuable upon the exercise of all outstanding warrants and other convertible securities or instruments issued by the Company, but excluding all shares of capital stock issued, issuable or reserved for issuance pursuant to or under the Company's 2005 Stock Incentive Plan and the Company's 2007 Equity Incentive Plan and excluding the shares of Common Stock issuable upon conversion of the Series A Preferred Stock), by (b) the closing sale price of a share of Common Stock, as reported on the over-the-counter bulletin board, or, if the Common Stock has been admitted to trading on a nationally recognized stock exchange or market quotation system (including, without limitation, the American Stock Exchange), as reported on such exchange or market quotation system, shall, during any forty-five (45) trading days within any consecutive ninety (90) day period, equal or exceed one hundred fifty million dollars ($150,000,000.00). Upon a Market Capitalization Contingency, the number of shares of Common Stock into which the outstanding Series A Preferred Stock is convertible shall be determined by dividing (x) 2.50, by (y) $0.50 (the "Market Cap Conversion Price"). Accordingly, the initial conversion ratio using the Market Cap Conversion Price will be five shares of Common Stock for one share of Series A Preferred Stock. The Basic Conversion Price and the Market Cap Conversion Price may be referred to herein as the "Conversion Price." The Conversion Price may be adjusted as set forth below.

Adjustments to the Conversion Ratio. In the event of the subdivision of our Common Stock (by forward stock split, stock dividend or other similar occurrence) into a greater number of shares of Common Stock, and no equivalent subdivision or increase is made with respect to the Series A Preferred Stock, the Conversion Price that in effect will be proportionately decreased. In the event of the combination (by reverse stock split or otherwise) or consolidation of our Common Stock into a lesser number of shares of Common Stock, and no equivalent combination or consolidation is made with respect to the Series A Preferred Stock, the conversion ratio then in effect will be proportionately increased. In the event of the issuance of rights or warrants to holders of Common Stock entitling them to subscribe for or purchase Common Stock, or the distribution of capital stock (other than shares of Common Stock) to holders of Common Stock, evidences of indebtedness of the company, assets, rights or warrants to subscribe for or purchase any securities, the holders of Preferred Stock will be entitled to receive, upon any conversion, the amount of the securities, assets, rights or warrants that they otherwise would have received had the Preferred Stock been converted at the time of such. issuance. Upon receipt of such issuance or distribution, no adjustment shall be made in the Conversion Price.

In the event of any capital reorganization or reclassification of our Common Stock (other than as a result of a stock dividend, subdivision, combination of shares or any other event described in the immediately preceding paragraph), or any sale or merger of our Company effected in such a way that holders of Common Stock become entitled to receive capital stock, other securities or property with respect to or in exchange for shares of Common Stock, the holders of Series A Preferred Stock will be entitled to receive, upon any conversion, the kind and number of shares of capital stock, other securities or property to which such holders of Series A Preferred Stock would have been entitled had they held the number of shares of Common. Stock into which the shares of Series A Preferred Stock then convert.

Automatic Conversion upon Certain Reorganizations, Mergers, etc. If there is any reorganization, recapitalization, consolidation, sale or merger involving the Company (i) that results in the stockholders of the Company immediately prior to such transaction owning less than 50% of the outstanding voting securities of the Company (or the surviving company in a merger) or (ii) in which transaction the Company is valued at at least one hundred fifty million dollars ($150,000,000.00) (in either case, a "Market Cap Transaction") in which the Common Stock (but not the Series A Preferred Stock) is converted into or exchanged for capital stock, other securities or property with respect to or in exchange for shares of Common Stock, then, immediately prior to any such Market Cap Transaction, all outstanding shares of Series A Preferred Stock will, without any further action by the Company or any holder of Series A Preferred Stock, automatically be converted into Common Stock at the then-applicable Market Cap Conversion Price, assuming a Market Capitalization Contingency had occurred, such that, upon the conversion or exchange of Common Stock in connection with such Market Cap Transaction, each holder of Series A Preferred Stock will be entitled to receive the kind and number of shares of capital stock, other securities or property to which such holders of Series A Preferred Stock are entitled taking into account such conversion of the Series A Preferred Stock as provided herein.

Treatment of the Series A Preferred Stock in the Event of Certain Mergers or Reorganizations, etc. If there is any reorganization, recapitalization, consolidation, sale or merger involving the Company that is not a Market Cap Transaction (a "Basic Transaction") in which the Common Stock (but not the Series A Preferred Stock) is converted into or exchanged for capital stock, other securities or property with respect to or in exchange for shares of Common Stock, then, immediately prior to any such Basic Transaction, all outstanding shares of Series A Preferred Stock will, as applicable: (i) remain outstanding if the Company is the surviving Company in such Basic Transaction, or (ii) be converted into shares of preferred stock of the surviving corporation in such Basic Transaction (if not the Company), with such shares of preferred stock to have the same powers, preferences and rights and relative, participating optional or other rights, preferences, restrictions and other matters relating to such series of preferred stock as provided herein

Fractional Shares. No fractional shares of Common Stock will be issued upon the conversion of the Series A Preferred Stock. Instead, all shares of Common Stock (including fractions thereof) issuable upon conversion of more than one share of Series A Preferred Stock by a holder thereof shall be aggregated and then will be rounded up to the nearest whole share. We will not pay any cash adjustment for fractional shares.

Voting Rights. The holders of Series A Preferred Stock (and the holders of any other class or series of preferred stock that may have similar voting rights) will vote on an as-if-converted basis with the holders of our Common Stock and any other class or series of preferred stock or Common Stock that by its terms, votes on an as-if-converted basis with the holders of our Common Stock on all matters to be voted on by stockholders of our company, subject to the provisions of the Nevada Revised Statutes. In addition, the holders of the Series A Preferred Stock shall vote as a separate class when required by Nevada law.

Dividends. Dividends will be payable only if, when and as declared by our Board of Directors, and, if declared, any such dividends will be non-cumulative. Such dividends, if any, will be paid out of, and to the extent of, any assets legally available therefor. No dividends will be declared or paid on the Common Stock, unless a dividend, payable in the same consideration or manner, is simultaneously declared or paid, as the case may be, on each share of Series A Preferred Stock.

Liquidation. In the event of any liquidation, dissolution or winding-up of our company (each, a "Liquidation"), whether voluntarily or involuntarily, the entire remaining assets and funds of the Company legally available for distribution, if any, shall be distributed pro rata among the holders of the Series A Preferred Stock (based upon the number of shares of Common Stock that such holders would have the right to acquire upon conversion of the Series A Preferred Stock at the Market Cap Conversion Price, assuming a Market Capitalization Contingency had occurred), the Common Stock and any other classes entitled to participate with Common Stock in proportion to the shares of Common . . .

Item 9.01 Financial Statements and Exhibits.
(c) Exhibits

Exhibit No. Description

4.1 Certificate of Designations of Preferences, Rights
and Limitations of Series A Convertible Preferred
Stock (filed herewith)

10.1 Securities Purchase Agreement among Modigene Inc.,
Frost Gamma Investments Trust, Jane Hsiao, Steven D.
Rubin and Subbarao Uppaluri (filed herewith)

10.2 Credit Agreement between Modigene Inc. and The Frost
Group, LLC (filed herewith)


Exhibit No. Description
10.3 Note and Security Agreement between Modigene Inc.
and The Frost Group, LLC (filed herewith)

99.1 Press Release, dated March 27, 2008.

[tsylver]

Modigene's Shot in the Arm
By Rachel Neiman
April 09, 2008

No one likes getting jabbed, but for many there isn't a choice. Millions of people get daily injections of therapeutic proteins, a group that encompasses everything from insulin to fertility drugs.

The problem faced by patients enduring multiple injections is how to get these therapies to last longer. The danger faced by drug developers wishing to increase "persistence", is that the body will develop an immune response to the molecule, rendering it useless.

Therapeutic proteins are defined as proteins engineered in the laboratory for pharmaceutical use. These fall roughly into two categories: replacement therapies for people whose bodies can't produce the proteins or produce insufficient amounts; and therapies that don't exist naturally in the body but - as in the case of monoclonal antibodies - can be cloned from a single cell to bind to and destroy antigens.

Once in the bloodstream, therapeutic proteins are quickly broken down and filtered out, so injections must be administered frequently to be effective.

Israel's Modigene, which just raised an additional $12 million from its investors, deals with replacement and enhancement therapies, and intends to develop longer acting versions of already-approved therapeutic proteins that will dramatically reduce the number of injections needed (i.e. from daily to weekly or less).

To that end, Modigene licensed intellectual property (IP) from Washington University of St. Louis. The technology is based on a short amino acid sequence, the carboxyl terminal peptide (CTP) that occurs naturally in humans. When attached to a therapeutic protein, CTP extends the time the protein is active in the body.

Modigene's license is for rights relating to human therapeutics including all therapeutic proteins and peptides, excluding four endocrine proteins. These were licensed, for fertility applications only, to Dutch company Organon, a unit of Schering-Plough. Organon's Phase II trials are encouraging: CTP follicle stimulating hormone product (FSH-CTP) required only one injection, compared with seven injections required for regular FSH.

The two companies are the only licensees of the technology, notes Modigene president Shai Novik, and while there is no formal relationship, "We follow them very closely because they are a clinical validation of the technology. We use the exact same CTP peptide but they are fusing it to FHS and we fuse it to other molecules."

Modigene currently has four CTP-enhanced compounds in development: MOD-701 - Erythropoietin to stimulate red blood cell production; MOD-901 - Interferon ß to treat multiple sclerosis (MS); MOD-1001 - GLP-1 for treatment of Type 2 diabetes and MOD-401 - Human Growth Hormone, to treat children with growth hormone deficiency, kidney disease, Prader-Willi Syndrome, and Turner's Syndrome. Israel's Office of the Chief Scientist awarded Modigene development grants for HGH-CTP in 2007 and for EPO-CTP in 2006.

HGH-CTP could have an additional market; it is being touted as a fountain of youth for adults that could increase energy, enhance sexual performance, lower cholesterol, and plump aging skin.

Novik says Modigene is watching but not targeting the lifestyle market, preferring to stay on track for FDA approval with human trials for HGH-CTP scheduled for the first quarter of 2009, and hopes of market launch in five years. "That's not a long time for drug development as we're seeking approval for an existing drug. Fast time-to-market at lower cost is part of our strategy."

In addition to commercializing its core therapeutic proteins, Modigene is also seeking licensing deals with biotechnology companies interested in developing longer-lasting versions of their existing drugs.

Modigene, which is publicly traded on Wall Street (MODG), operates an R&D subsidiary at the Weizmann Science Park, Ness Ziona.

Modigene's chairman and lead investor is Miami-based entrepreneur Dr. Phillip Frost, listed among Forbes 400 Richest Americans for 2007. Frost is chairman of Ladenburg Thalmann & Co. Inc. and a director of Continucare Corp. (CNU) and Teva Pharmaceutical Industries.

The $12 million investment consists of a $2 million equity investment by Frost, Dr. Jane Hsiao and Steven Rubin, who are also directors at Modigene and members of The Frost Group LLC, which extended the additional $10 million line of credit.

source: http://www.israel21c.org/bin/en.jsp?enDispWho=Articles%5El20…

[tsylver]

Form 10-Q for MODIGENE INC.
http://biz.yahoo.com/e/080513/modg.ob10-q.html" target="_blank" rel="nofollow ugc noopener">
http://biz.yahoo.com/e/080513/modg.ob10-q.html

[tsylver]

Modigene to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

ES-ZIONA, Israel, May 15 Modigene-Presents

NES-ZIONA, Israel, May 15 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG), a biopharmaceutical company applying its patented technology to develop longer-acting versions of already approved therapeutic proteins, today announced that President Shai Novik will present at the upcoming Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference at 3:40 AM EDT (9:40 AM Central European Summer Time) on May 20, 2008.

The presentation will be webcast live and an archived version of the webcast will be available for approximately 90 days. The live and archived webcast can be accessed at http://wsw.com/webcast/rrshq13/modg.ob.

[tsylver]

MODIGENE PLATFORM VALIDATED IN INDEPENDENT
PHASE III TRIAL OF CTP TECHNOLOGY--Validates the Clinical Utility of Modigene’s CTP Technology for
Extending the Duration of Action of Therapeutic Proteins--

Nes-Ziona, Israel -- July 10, 2008 -- Modigene Inc., (OTCBB: MODG) today noted the
successful completion of a Phase III clinical trial by Schering-Plough of long-acting fertility
hormone corifollitropin alfa (FSH-CTP). FSH-CTP uses the naturally occurring CTP peptide
to extend the duration of action of the hormone. Modigene is using the same naturally
occurring CTP peptide to extend the duration of action of other therapeutic proteins and
peptides. Schering-Plough licensed the CTP technology from Washington University for use
only with four endocrine hormones. Modigene has an exclusive license from Washington
University to the CTP technology for use with all other proteins and peptides. Modigene is
currently applying the CTP technology to extend the duration of action of human growth
hormone and interferon beta, with the goal of reducing the number and frequency of
injections required to treat patients requiring continual injections of these proteins.
“The success of Schering-Plough’s Phase III trial of its long-acting FSH fertility hormone
marks a major milestone for the CTP platform technology that is the basis for our new drug
pipeline,” said Avri Havron, Ph.D., CEO of Modigene. “We believe these positive results
provide independent support of our own plans for clinical trials of Modigene’s CTP-enhanced
versions of human growth hormone and interferon beta that we intend to initiate next year.”
On July 8, 2008 Schering-Plough announced successful top-line data from its Phase III
ENGAGE trial demonstrating that women receiving a single injection of FSH-CTP achieved
the same pregnancy rates as women receiving seven consecutive daily injections of FSH, a
primary endpoint of the study. This 1,509 patient trial was the largest double-blind fertility
trial ever conducted.
Human growth hormone (hGH), which is used to treat growth failure in children and frailty in
adults, must currently be injected between three and seven times per week, while interferon
beta (IFN-Beta), which is prescribed for the treatment of multiple sclerosis, must be injected
between one and three times per week. Neither of these therapies has a commercial longacting
version available, and their current market sizes are estimated at $2.2 billion and $4.3
billion, respectively.
Modigene’s hGH-CTP and IFN-Beta-CTP are in late preclinical development. Based on
studies in relevant animal models, researchers project once-weekly administration of hGHCTP
compared to the multiple daily injections required for commercial hGH, and once-every
two-to-four weeks administration of IFN-Beta-CTP, compared to the one-to-three times per
week injections currently required for commercial interferon beta.
ABOUT MODIGENE
Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to
develop longer-acting, proprietary versions of already approved therapeutic proteins that
currently generate billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins, and Modigene is currently developing long-acting versions
of human growth hormone, interferon beta and erythropoietin, which are in late preclinical
development, as well as GLP-1. For more information on Modigene, visit
www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including
statements regarding the results of current studies and preclinical experiments and the effectiveness
of Modigene’s long-acting protein programs and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking
statements involve risks and uncertainties that may affect Modigene’s business and prospects,
including the risks that Modigene may not succeed in developing any commercial products based
upon its long-acting protein technology, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may
not achieve the expected results or effectiveness and/or may not generate data that would support
the approval or marketing of these products for the indications being studied or for other indications;
that ongoing studies may not continue to show substantial or any activity; that the actual dollar
amount of any grants from the OCS is uncertain and is subject to policy changes of the Israeli
government, and that such grants may be insufficient to assist with product development; and other
risks and uncertainties that may cause results to differ materially from those set forth in the forwardlooking
statements. The development of any products using the CTP platform technology could also
be affected by a number of other factors, including unexpected safety, efficacy or manufacturing
issues, additional time requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of
patents and other proprietary rights held by competitors and other third parties. In addition to the risk
factors set forth above, investors should consider the economic, competitive, governmental,
technological and other factors discussed in Modigene’s filings with the Securities and Exchange
Commission.
MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: [phone] [phone]
Email: [e-mail]

[tsylver]

Antwort auf Beitrag Nr.: 34.492.121 von tsylver am 11.07.08 20:07:40

...deshalb hat sich der Kurs innerhalb von ein paar Tagen rund verdoppelt...

und Doc Frost ist auch fleissig am einsammeln

[tsylver]

CTP is "best-of-breed" for enhancing protein longevity
By Gareth Macdonald

16-Jul-2008 - Modigene says that data from a trial of a Schering-Plough's (SP) fertility stimulation hormone (FSH-CTP) confirms that carboxyl terminal peptide (CTP) modification can extend the therapeutic duration of protein drugs.

Techniques to boost the half-life of therapeutic proteins fall into two main categories with developers choosing to either increase the size of the drug molecule or alter its physical structure in an effort to extend its durability in circulation.

Such approaches are fraught with technical difficulties and, to date, only a handful of extended-release drugs have been commercialized. Despite this, products that have been launched, such as SP's Pegintron (peginterferon alfa-2B), Amgen's Aranesp (Darbepoetin alfa) and Neulasta (PEGfilgrastim), generate revenues of around $8bn a year.

The CTP approach, which was developed by researchers working at Washington University in St. Louis, Missouri, attaches a small portion of the female pregnancy maintenance hormone chorionic gonadotropin (hCG) to the molecule under development, markedly improving its circulatory half-life.

Shai Novik, Modigene's president, told in-PharmaTechnologist.com that: "The CTP peptide is basically a best-of-breed technology to enhance protein longevity. PEGylation, DNA mutations and Albumin fusion are the technologies that have mainly been used to date, and CTP has the positive properties encapsulated in each, but is a natural peptide we all carry in our bodies and therefore non-immunogenic."

"The three main important properties of a technology to extend protein longevity are: Create a durable protein; that maintains comparable biological activity; and is non-immunogenic. The CTP offers all three in a small peptide that can be attached once or multiple times to a protein of choice to extend durability. Unlike technologies like PEGylation and DNA mutation, which involve trial-and-error to find the right combination that may work, the CTP technology is a simple attachment of the CTP peptide to the authentic molecule," Novik explained.


He added that because: "the CTP platform is applicable to all therapeutic proteins and peptides. The market for the proteins we are currently going after is $2.2bn for human growth hormone, and $4.3bn for interferon beta. There are many other therapeutic proteins representing over $50bn in annual sales."

Clinical trials due next year

SP's Phase III trial, known as ENGAGE, compared the effectiveness of a single FSH-CTP in 1,509 women suffering from a variety of fertility problems. The results showed that pregnancy rates in subjects who received the single injection were comparable with those who received seven consecutive FSH injections.

Modigene is applying the CTP technology to its human growth hormone (hGH) and interferon beta (IFN-beta) programmes. Specifically, the firm is seeking to establish products that require only once-a-week administration, in contrast with the three to seven times a week injections demanded by currently available competitor treatments.

Company CEO, Avri Havron, said that the: "The success of Schering-Plough's Phase III trial of its long-acting FSH fertility hormone marks a major milestone for the CTP platform technology that is the basis for our new drug pipeline."

"We believe these positive results provide independent support of our own plans for clinical trials of Modigene's CTP-enhanced versions of human growth hormone and interferon beta that we intend to initiate next year," he added.

[tsylver]

Form 8-K for MODIGENE INC.

18-Jul-2008

Change in Directors or Principal Officers, Financial Statements and Exhibits


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) On July 17, 2008, the Compensation Committee of the Board of Directors of Modigene Inc. (the "Company") approved certain amendments to the employment agreements, as previously amended, of four of its Israeli executives, namely Shai Novik (President), Avri Havron (Chief Executive Officer), Fuad Fares (Chief Scientific Officer) and Eyal Fima (VP Product Development) (together, the "Israeli Executives"). The employment agreements with the Israeli Executives are referred to collectively as the "Israeli Executive Employment Agreements."

The amendments to the Israeli Executive Employment Agreements were entered into to provide that effective June 1, 2008, the compensation of the Israeli Executives would be modified from United States Dollars (US$) to Israeli Shekels (IS), calculated using an IS/US$ exchange rate of 3.86 IS/US$. As to the compensation of each of the Israeli Executives, the compensation payable in IS is as follows:

Avri Havron: Salary of 829,900 IS, Bonus of 231,600 IS

Shai Novik: Salary of 965,000 IS, Bonus of 328,100 IS

Eyal Fima: Salary of 386,000 IS, Bonus of 193,000 IS

Fuad Fares: Salary of 138,960 IS

The amendments were entered into because under the Israeli Executive Employment Agreements, the salary was previously stated in US$, but was paid in IS based on the prevailing IS/US$ exchange rate. All of the Israeli Executives reside in Israel and perform substantially all of their services to the Company in Israel. Accordingly, the Compensation Committee adopted the amendments in order to reflect the intention of the Company that the Israeli Executives be paid in the currency of the country in which they reside, and to avoid any fluctuations in salary that could potentially result from currency exchange rate fluctuations.





Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

Exhibit No. Description

10.1 Amendment to Consulting Agreement
between the Company and Avri Havron
10.2 Amendment to Employment Agreement
between the Company and Shai Novik
10.3 Amendment to Consulting Agreement
between the ModigeneTech Ltd. and Fuad
Fares
10.4 Amendment to Employment Agreement
between the ModigeneTech Ltd. and Eyal
Fima

[tsylver]

Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
Tuesday August 5, 8:00 am ET
- $25 Million Interferon-Beta-CTP Development Program Has Been Approved For First Year Funding Through a Special Grant From the Israeli Office of the Chief Scientist -


NES-ZIONA, Israel, Aug. 5 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG - News) today reported that its Israeli-based R&D subsidiary has received approval for a special grant from the Israeli Office of the Chief Scientist ("OCS") in support of the company's development program for interferon-beta-CTP (IFN-Beta-CTP), its longer-acting version of interferon beta. Interferon-beta is an injectable treatment for multiple sclerosis (MS).

In preclinical experiments, IFN-Beta-CTP has shown durability of therapeutic effect, or half-life, almost seven times greater (6.7-fold longer) than the durability of effect of commercial interferon beta. The data demonstrated the potential to significantly reduce the number of required injections of interferon beta, which would greatly increase patient convenience.

The OCS has approved a special grant to support Modigene's IFN-Beta-CTP program for 2008-2009. The grant will provide cash reimbursements of 40% of expenses paid for IFN-Beta-CTP product development during this period. Modigene's full IFN-Beta-CTP development program, as submitted to the OCS, is based on an estimated development budget of $25 million for calendar years 2008-2011. IFN-Beta-CTP is currently in preclinical development, with clinical trials expected to begin in 2009.

Interferon beta is a drug used to reduce the frequency and severity of relapses afflicting people suffering from MS, an autoimmune neurological disorder affecting the insulating myelin layers of the brain and spinal cord. If unchecked, over time the immune system attack on myelin leads to poor coordination, severe disabilities and premature death. Annual sales of interferon beta were estimated to be $4.3 billion in 2007.

"This generous new grant from the OCS is an important non-dilutive cash resource for Modigene and represents another validation of the potential of our technology and of our second lead candidate," said Abraham Havron, Ph.D., Chief Executive Officer of Modigene. "The OCS has already awarded Modigene funds in support of our human growth hormone (hGH-CTP) product candidate and we are delighted that our IFN-Beta-CTP program has now also been selected for support. This visionary OCS program is particularly attractive for Modigene because it does not require any repayment until the product is generating revenue. We are grateful for this valuable source of non-dilutive capital."

Under the terms of the grant, Modigene is required to repay the OCS the sum of the grant plus accrued interest through a series of payments that begin only upon successful commercialization of the IFN-Beta-CTP product, or other products developed at the company with its CTP technology.

ABOUT CTP

Modigene's technology was discovered by researchers at Washington University in St. Louis and is based on a short amino acid sequence, the Carboxyl Terminal Peptide (CTP). CTP occurs naturally in humans and when attached to a therapeutic protein, extends the time that the protein is active in the body. The potential utility of the technology has been demonstrated by Schering-Plough, which licenses the CTP technology for fertility applications only. On July 8, 2008 it announced successful top-line data from its Phase III ENGAGE trial demonstrating that women receiving a single injection of the fertility drug FSH-CTP achieved the same pregnancy rates as women receiving seven consecutive daily injections of commercial FSH. This 1,509 patient trial was the largest double-blind fertility trial ever conducted. Modigene is using the same CTP technology to extend the duration of action of other therapeutic proteins. It has an exclusive license from Washington University to the CTP technology for use with all therapeutic proteins except for the four endocrine hormones licensed to Schering-Plough.

ABOUT MODIGENE

Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from the OCS is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene's filings with the Securities and Exchange Commission.


MODIGENE CONTACT: MEDIA CONTACT:
Shai Novik, President Barbara Lindheim
Modigene Inc. GendeLLindheim BioCom Partners
Tel: [phone] [phone]
Email: [e-mail]

--------------------------------------------------------------------------------
Source: Modigene Inc.

[tsylver]

Form 10KSB/A for MODIGENE INC.


13-Aug-2008

Annual Report



Item 6. Management's Discussion and Analysis of Financial Condition and Results of Operation
The following discussion should be read in conjunction with the consolidated financial statements and the related notes thereto that appear in Item 7 of this Annual Report on Form 10-KSB/A.

Management's Discussion and Analysis

Results of Operation

The section "Results of Operation -- Critical Accounting Policies" under Item 6 of the Form 10-KSB as filed on March 31, 2008, is replaced in its entirety by the following section:

Critical Accounting Policies

The historical financial statements of the Company included with this Annual Report have been prepared in accordance with accounting principles generally accepted in the United States. The significant accounting policies followed in the preparation of the financial statements, on a consistent basis, are described below.

Use of Estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Financial Statements in United States Dollars: The functional currency of the Company is, and of Modigene Delaware prior to the Merger has been, the U.S. dollar, as the U.S. dollar is the primary currency of the economic environment in which Modigene Delaware has operated and in which the Company expects to continue to operate in the foreseeable future. The majority of ModigeneTech's operations are currently conducted in Israel, and most of the Israeli expenses are paid in new Israeli schekels; however, most of the expenses are denominated and determined in U.S. dollars. Financing and investing activities, including loans and equity transactions, are made in U.S. dollars.

Accordingly, monetary accounts maintained in currencies other than the U.S. dollar are remeasured into U.S. dollars in accordance with Statement No. 52 of the Financial Accounting Standards Board ("FASB"), "Foreign Currency Translation." All transaction gains and losses from the remeasurement of monetary balance sheet items are reflected in the statements of operations as financial income or expenses, as appropriate.

Principles of Consolidation: The consolidated financial statements include the accounts of Modigene Delaware and its wholly-owned subsidiary, ModigeneTech. Intercompany transactions and balances have been eliminated upon consolidation.

Cash Equivalents: Cash equivalents include short-tem liquid investments that are readily convertible to cash with original maturities of three months or less.

Property and Equipment: Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated by the straight-line method over the estimated useful lives of the assets. The annual depreciation rates are as follows:


%

Office furniture and equipment 6

Laboratory equipment 15

Computers and electronic equipment 33

Leasehold improvements 25






--------------------------------------------------------------------------------

The Company's long-lived assets have been reviewed for impairment in accordance with Statement of Financial Accounting Standard No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets," whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets.

Research and Development Costs and Participation: Research and development ("R&D") costs are expensed as they are incurred and consist of salaries, benefits and other personnel related costs, fees paid to consultants, clinical trials and related clinical manufacturing costs, license and milestone fees, and facilities and overhead costs. R&D expenses consist of independent R&D costs and costs associated with collaborative R&D and in-licensing arrangements. Participation from government for development of approved projects are recognized as a reduction of expenses as the related costs are incurred.

Severance Pay: The liability of ModigeneTech for severance pay is calculated pursuant to the Severance Pay Law in Israel, based on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is presented on an undiscounted bases. ModigeneTech's employees are entitled to on month's salary for each year of employment or portion thereof. Severance expenses for the twelve month periods ending December 31, 2007 and 2006 and for the period from May 31, 2005 (inception date) through December 31, 2007 amounted to $6,911, $1,956, and $8,867 respectively.

Income Taxes: The Company accounts for income taxes in accordance with Statement of Financial Accounting Standard No. 109, "Accounting for Income Taxes." This statement prescribes the use of the liability method, whereby deferred tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company has provided a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.

Concentrations of Credit Risk: Financial instruments that potentially subjected the Company, Modigene Delaware and ModigeneTech to concentrations of credit risk consist principally of cash and cash equivalents.

Cash and cash equivalents are invested in major banks in Israel and the United States. Such deposits in the United States are not insured. Management believes that the financial institutions that hold the Company's investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.

The Company has no off-balance sheet concentration of credit risk such as foreign exchange contracts or other foreign hedging arrangements.

Fair Value of Financial Instruments: The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments: The carrying amounts of cash and cash equivalents, other receivables, trade payables and liabilities approximate their fair value due to the short-term maturity of such instruments.

Royalty-bearing Grants: Royalty-bearing grants from the Government of Israel for participation in development of approved projects are recognized as a reduction of expenses as the related costs are incurred. Funding is recognized at the time ModigeneTech is entitled to such grants, on the basis of the costs incurred.

Research and development grants received by ModigeneTech for the twelve month periods ending December 31, 2007 and 2006 and for the period from May 31, 2005 (inception date) through December 31, 2007 amounted to $272,282, $99,868, and $372,150 respectively.

Loss per Share: Basic and diluted losses per share are presented in accordance with Statement of Financial Accounting Standard No. 128 "Earning per Share." Outstanding share options and warrants have been excluded from the calculation of the diluted loss per share because all such securities are antidilutive. The total weighted average number of ordinary shares related to outstanding options and warrants excluded from the calculations of diluted loss per share were 5,262,819, 2,641,900 and 3,095,891 for the years ending December 31, 2007 and 2006 and for the period from May 31, 2005 (inception date) through December 31, 2007, respectively.

[Haendchen3]

Schaut mal, kam heute als Musterdepotwert im Global Biotech Investing von Börse Inside

Am Aktienkurs von MODIGENE zeichnet sich mehr und mehr
die Handschrift des findigen Biotechinvestors Phillip Frost ab!
Bereits seit dem Börsengang von Mai 2007 sitzt der brillante Investor
bei MODIGENE im Aufsichtsrat und holte sich bereits
damals im Rahmen einer Finanzierungsrunde ein paar Stücke zum
Preis von USD 1.50 pro Aktie ins Depot. Dazu müssen Sie wissen:
Schon mehrfach ist Frost in der Vergangenheit durch sein ausgesprochen
glückliches Händchen bei seinen Investmententscheidungen
aufgefallen. Sein Meisterstück machte Frost mit dem seinerzeitigen
Verkauf der Ivax Corp. an Teva Pharma für USD 7.4
Mrd., wo er seitdem mit im Board sitzt. Und möglicherweise wiederholt
sich nun diese überaus erfolgreiche Geschichte bei MODIGENE.
Allerdings trennten sich seither weder die Insider noch
Großaktionäre von ihren Titeln. Ganz im Gegenteil:
Seit Mitte Mai dieses Jahres kauft Dr. Phillip Frost weitere Aktienpakete
von MODIGENE zu und stockte somit seinen Anteil am Unternehmen auf
mittlerweile rund 13.50% auf! Anscheinend haben die Papiere von MODIGENE
für den gewieften und versierten Investor einen höheren Reiz, als die bisherige
Kursentwicklung vermuten lassen würde. Ein Blick auf das Geschäftsmodell
verrät uns auch weshalb: Das Unternehmen erforscht und entwickelt therapeutische
Proteine, die entweder aus menschlichen Zellen oder im Labor entwickelt
werden. Die FDA hat bislang erst 75 therapeutische Proteine, auch als Biopharmaka
bekannt, zugelassen. Weitere 500 Biopharmaka stecken derzeit in unterschiedlichen
Entwicklungsphasen. Das Marktpotenzial der therapeutischen Proteine wird
für dieses Jahr auf USD 70 Mrd. geschätzt. So weit, so gut. Das Problem liegt
jedoch in der Form der Verabreichung: Weil die Proteine nicht über den Magen-
Darm-Trakt eingenommen werden können, muss die Zuführung durch Injektion
erfolgen. Einmal im Blutkreislauf haben die Proteine aber mit Enzymen, Zellaktivitäten und den normalen
Filterfunktionen des menschlichen Körpers zu kämpfen. Um einen Behandlungserfolg zu erzielen, müssen die
Infusionen deshalb mehrfach wiederholt werden. Und genau an diesem Punkt setzt MODIGENE an:
Die Company testet mittels ihrer patentierten Technologie die Modifikation bereits erprobter therapeutischer
Proteine, um die Anzahl der Behandlungen zu reduzieren! Das erspart nicht nur den Patienten eine
langwierige Therapie, sondern dadurch eröffnen sich auch der Company ungemeine Chancen. Welche Auswirkungen
positive News zu diesem Thema auf den Aktienkurs haben, erlebten wir zuletzt in Barcelona: Hier
präsentierte der Pharmariese Schering- Plough überragende Phase III-Ergebnisse in einer der größten klinischen
Hormonuntersuchungen, die jemals durchgeführt wurden. Doch inwiefern betrifft das MODIGENE? Nun, MODIGENE
schloss seinerzeit einen Lizenzvertrag über die CPT-Technik mit Organon ab, die zwischenzeitlich von
Schering-Plough übernommen wurde. Und genau diese CPT-Technik war der Schlüssel zum Erfolg der aktuellen
Testreihen von Schering-Plough. Der Aktienkurs von MODIGENE schoss als Reaktion auf die tollen Ergebnisse
auf USD 1.50, da sich dieses Konzept erstmals als verlässlich herausgestellt hat und die in den Startlöchern
steckenden Phase I-Testreihen der Company nun unter einem ganz anderen Licht stehen. Die Analysten von
Roth Capital erhöhten daraufhin prompt ihr Kursziel von USD 2.50 auf USD 4 pro Aktie – mithin ein Potenzial
von mehr als 160%! (WKN A0M SLD, Kurs aktuell EUR 1.02, Reuters MODG)

Liest sich richtig gut die Story! Der Chart passt zudem!
Momentan echt ne Option, meint ihr nicht?
Gruß
Haendchen

[tsylver]

Form 8-K for MODIGENE INC.

22-Sep-2008
Regulation FD Disclosure, Financial Statements and Exhibits



Item 7.01 Regulation FD Disclosure.
On or about September 22, 2008, Modigene Inc. (the "Company") will be mailing a letter to the record holders of its common stock regarding the Company's operations and product development plans. A copy of the letter is attached hereto as Exhibit 99.1.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.



Item 9.01 Financial Statements and Exhibits.
(c) Exhibits


September 22, 2008


Dear Fellow Shareholders:


We would like to take this opportunity to provide you with an update on the accomplishments achieved at Modigene over the last 12 months as well as our future plans. During this period, Modigene advanced its lead preclinical programs, increased the company’s financial resources through a capital infusion and the award of potentially sizeable non-dilutive development grants, witnessed a major clinical validation of the potential of the technology underlying its programs and strengthened its Board of Directors. Modigene is now well positioned to execute on its product development plans, which we believe have the potential to generate significant value for our shareholders.

Product & Clinical Development

We made substantial progress over the past year in advancing our lead product candidates based on our CTP technology that has the potential to significantly increase the duration of action of therapeutic proteins, and we anticipate filing an IND for our first human clinical trial in the first quarter of next year.

Long-Acting Human Growth Hormone: Currently available human growth hormone for treating growth hormone deficiency in children must be injected daily. Our human growth hormone drug candidate, hGH-CTP, has a potential to be injected only once every one or two weeks, providing a significant benefit to patients and their families. The market potential is large—the current estimated market size for short-acting growth hormones is $2.2 billion. During the past year, we successfully developed a small-scale production process for hGH-CTP in Modigene’s laboratories. The process is currently being scaled-up and product is now being prepared for pre-clinical and clinical development. We anticipate submitting an IND to the FDA for regulatory permission to initiate clinical trials in Q1/2009. We expect a Phase I trial to be completed in about 90 days.

Long-Acting Interferon-β: Interferon-ß is a mainstay of treatment for multiple sclerosis. Our drug candidate IFN-ß-CTP has an almost 10-fold duration in the blood in animal models compared to the current commercial product. The current estimated market for interferon-β is $4.3 billion. We are now completing the small-scale development process for IFN-ß-CTP. We expect to file an IND for our IFN-ß-CTP in Q3/2009, and to initiate clinical trials soon thereafter.

Long-Acting EPO: Despite an eventful year and some turmoil in the erythropoietin (EPO) market, EPO continues to be widely used for patients with cancer and kidney disease, and the annual EPO market is estimated at $10 billion. In validated animal models, our EPO-CTP drug candidate has a 33% greater longevity than Amgen’s commercial long-acting EPO - Aranesp®. We plan to continue the development of EPO-CTP in partnership with a leading pharmaceutical company. Negotiations with several potential partners are ongoing.


--------------------------------------------------------------------------------

Modigene Inc. 3 Sapir Street, Weizmann Science Park, Nes Ziona Israel 74140
1
--------------------------------------------------------------------------------

Exhibit 99.1


Additional Product Pipeline

Modigene is currently developing and testing long-acting versions of the following drug candidates:

GLP-1-CTP: The GLP-1 therapeutic peptide occurs naturally in the human body. It is derived from proglucagon - a hormone secreted by the intestines, and serves to maintain healthy blood sugar levels and control appetite. GLP-1 currently is marketed to treat Type 2 diabetes, acting to decrease both the weight gain and the incidence of hypoglycemia that can arise as side effects of current diabetes treatments. Its clinical use has likely been adversely impacted by the fact that in its current pharmaceutical form it has to be injected twice daily. GLP-1 also has potential in other indications such as obesity. The estimated market for short-acting GLP-1 is $0.5 million. A longer-acting version is expected to have considerably greater market potential.

Factor VII-CTP: The main function of Factor VII is to initiate the process of blood coagulation. It is currently indicated for use in chronic haemophilia patients to control bleeding. The estimated market for short-acting Factor VII is $1.0 billion.

Phase III Validation of CTP Technology

Schering-Plough announced on July 8, 2008 that its Phase III ENGAGE trial, which assessed the efficacy and safety of a long-acting fertility drug (that uses the same CTP technology being developed by Modigene) successfully met its two primary endpoints, including successful pregnancies. This clinical trial, which included 1,509 patients, was the largest double-blind fertility trial ever conducted. In earlier studies Schering-Plough has shown that linking the naturally-occurring peptide CTP to FSH, a fertility hormone, can successfully extend the activity of the hormone, enabling a single injection of FSH-CTP to replace seven consecutive daily injections of standard FSH. Modigene has rights to the CTP technology for all but four endocrine proteins previously licensed by Schering-Plough from Washington University in St. Louis.

Schering-Plough’s Phase I, II, and III studies demonstrated that attaching the CTP peptide did not affect the therapeutic activity of FSH or cause a negative immune system response. Modigene is using the same naturally occurring CTP peptide to extend the duration of action of other therapeutic proteins and peptides. We view these findings of great significance to Modigene as they provide further clinical validation of our technology. We look forward to initiation of our clinical studies of hGH-CTP and interferon-β-CTP.

OCS Grants

Modigene has been proactive in seeking sources of non-dilutive funding for our development programs. In November 2007, we received approval from the Office of the Chief Scientist of the Israeli government (OCS) for a grant supporting the product and clinical development of our long-acting human growth hormone drug candidate. The grant will provide cash reimbursements of 30% to 50% of our development expenses for the hGH-CTP product. The project budget is estimated at $10 million over four years. In addition, in August 2008 we received approval from the OCS for a second grant supporting the first year product and clinical development of our long-acting interferon-β drug, with cash reimbursements of 40% of our development expenses. The project budget is estimated at $25 million over four years.


--------------------------------------------------------------------------------

Modigene Inc. 3 Sapir Street, Weizmann Science Park, Nes Ziona Israel 74140
2
--------------------------------------------------------------------------------

Exhibit 99.1


Liquidity & Resources

Our company’s current financial position is sound. In March, Modigene completed an equity and debt financing by members of the Frost Group on terms that we considered favorable to the company. With over $11 million of cash as of August 1, 2008, and an option to borrow up to an additional $10 million from the Frost Group, along with the non-dilutive cash grants we have been awarded from the Israeli Office of the Chief Scientist, we believe that Modigene’s capital structure is robust. Our current resources are expected to provide the company with up to two years of liquidity to support our product and clinical development plans. According to our current plans, this should be adequate to take us through the end of Phase II clinical trials with at least one of our long-acting drug candidates.

Board of Directors

We have significantly reinforced our board of directors via the appointment in March of Dr. Phillip Frost as Executive Chairman, and new directors Dr. Marian Gorecki and Mr. Steven Rubin replacing Dr. Eugene Bauer and Mr. Joel Kanter.

Dr. Frost currently serves as Chairman and CEO of OPKO Health, Inc., a publicly traded specialty healthcare company. He also serves as Chairman of Ladenburg Thalmann & Co. Inc., as Vice Chairman of Teva Pharmaceuticals, and as a director of Northrop Grumman Corporation and Continucare Corporation. He is a trustee of the University of Miami, the Scripps Research Institute, the Miami Jewish Home for the Aged and the Mount Sinai Medical Center; a regent of the Smithsonian Institute, and Vice Chairman of the Board of Governors of the American Stock Exchange. Previously, Dr. Frost was Chairman and CEO of IVAX Corporation, which he founded in1987, until the company’s acquisition by Teva Pharmaceuticals in 2006.

Dr. Marian Gorecki, a 30-year veteran of the biotechnology industry, is currently Chairman of Thrombotech, a company developing a peptide to mitigate the side effects of standard stroke treatments. Previously, Dr. Gorecki co-founded and served as General Manager and Board member of Bio Technology General (BTG), now Savient Pharmaceuticals Inc. He also served as Chairman and CEO of Mediwound Ltd., a biotechnology company developing enzyme-based products in the fields of burn and wound management. Dr. Gorecki was responsible for overseeing the clinical development, regulatory approval and commercialization of five biotechnology drugs that are currently marketed, as well as two that are now in Phase III trials. Dr. Gorecki is the inventor of 21 issued patents and author of 73 peer-reviewed scientific articles.

Steven D. Rubin, J.D., is currently Executive Vice President-Administration and a director of OPKO Health, Inc. He currently also serves as a director of SafeStitch Medical Inc., a medical device company, of Dreams Incorporated, a manufacturer and provider of licensed sports products, of Ideation Acquisition Corp., a special purpose acquisition company, of Kidville, Inc., an owner and operator of upscale learning and play facilities for children, and of Cardo Medical, an orthopaedic medical device company. Previously, he was Senior Vice President and General Counsel of IVAX.


--------------------------------------------------------------------------------

Modigene Inc. 3 Sapir Street, Weizmann Science Park, Nes Ziona Israel 74140
3
--------------------------------------------------------------------------------

Exhibit 99.1


12-Month Operating Plan

We are focused on executing our operating plan to meet a number of important milestones, with the priority of beginning Phase I clinical trials for our long acting human growth hormone and then submitting the IND for our long-acting interferon-β candidate. With a strong capital position, dedicated and experienced board and management team, and with the exciting results we have seen to date from our drug candidates, we believe Modigene is now well positioned to execute our product development plans and to begin to realize the full potential of our innovative technology. We appreciate your continuing support of Modigene and look forward to updating you on our progress in the coming months.


Sincerely,

Dr. Abraham Havron
Chief Executive Officer

Dr. Phillip Frost
Chairman

Modigene Inc.


Safe Harbor Statement: This letter contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene’s long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene’s business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from the OCS is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors set forth above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Modigene’s filings with the Securities and Exchange Commission.

--------------------------------------------------------------------------------

Modigene Inc. 3 Sapir Street, Weizmann Science Park, Nes Ziona Israel 74140

[BikiniAnalyst]

Antwort auf Beitrag Nr.: 35.024.663 von Haendchen3 am 08.09.08 14:14:47

Ja, scheint wieder interessant zu werden.

[Macos]

Analyse vom letzten Jahr!


http://www.firstcapitalresearch.com/site/research%20german_f…

Gruss macos

[Macos]

Heute fette Umsätze in den USA, ist der Boden erreicht?

[tsylver]

Antwort auf Beitrag Nr.: 35.811.856 von Macos am 03.11.08 16:11:55

rund der 30-fache Umsatz.
wer kauft sich da ein?
das meiste ist über den Schlusskurs von letzte Woche gekauft worden. der kurs ging erst zum Ende runter

[Macos]

Antwort auf Beitrag Nr.: 35.816.416 von tsylver am 03.11.08 22:44:37

Frost hat seit August über 1 Mio Aktien gekauft